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 ABSTRACT: 
 
Ataxia telangiectasia (A-T) is an autosomal recessive disorder associated with early 
childhood ataxia, neurodegeneration, immune deficiency, radiosensitivity, sterility, and an 
increased susceptibility to cancer.  In spite of numerous years of research, there is still no 
curative treatment for A-T, nor a reliable animal model that recapitulates the prominent 
neurological phenotypes observed in patients. To address these deficiencies and investigate 
potential therapeutic approaches I have attempted to generate a universal donor pluripotent 
stem cell line, utilized radiological imaging to investigate a novel rat model of A-T, and 
tested whether bone marrow transplantation (BMT) could provide benefit in the treatment of 
hematological defects associated with A-T.  
 
Cells derived from pluripotent stem cell populations may provide a novel approach to therapy 
in this disease. Universal embryonic stem cell donor lines would greatly facilitate stem cell 
based regenerative medicine and permit facile testing of human pluripotent stem cell derived 
grafts in xenogeneic settings. Because HLA-G overcomes immune cell mediated attack of 
foetal tissues during pregnancy and inhibits T-cell responses and dendritic cell antigen 
maturation in vitro and in vivo, it is an attractive candidate molecule for achieving this goal. 
Here we investigated whether enforced expression of either the soluble or the membrane bound 
form of the HLA-G mouse homologue, H2-Bl, in human and mouse ES cell lines would allow 
engraftment in immunocompetent mice. Despite evidence for robust expression of soluble or 
membrane bound H2-Bl molecules and effective inhibition of CD8+ T-cell proliferation by all 
H2-Bl engineered ES cell lines, all failed to generate teratomas in immunocompetent mice, 
despite doing so in NOD-SCID mice. We conclude that expression of H2-Bl in human and 
mouse embryonic stem cells alone is insufficient to overcome xenogeneic rejection. 
 
Animal models are likely to play a key role in the development of therapeutic strategies for the 
treatment of A-T. While multiple mouse models of A-T currently exist and recapitulate some 
of the phenotypes attributed to the human disease, prominent neurodegeneration has not been 
observed in these animal. As such, our research group has produced a gene knock-out model 
in the rat, utilizing Zinc Finger Nuclease technology. Approximately 50% of the Atm -/-  rats 
show dilated blood vessels in the eyes, microgliosis, and develop hind limb paralysis, 
suggesting this model may recapitulate some of the  neurological defect observed in A-T 
patients. Magnetic resonance imaging (MRI) was utilized to assess structural changes in the 
brain and spinal cord. Surprisingly, no significant differences in cerebellar volume or 
gray/white matter ratios were observed in the brain or spinal cord of healthy animals.  
However, lymphomas were detected in the T12-L3 region of the spine in all of the 
paralysed animals tested. I utilized PET/MRI in conjunction with the radiotracer 
(18F)PBR111, which is highly selective for the TSPO receptor of activated microglia in the 
brain, to assess microglial activation in vivo in 5 month old control and ATM null non –
paralysed rats, three of each. No differences were observed in the cerebellum of these 
rats relative to WT rats, as well as multiple other brain regions assessed in healthy 
animals. These data provide evidence that paralysis in the A-T rat model is associated 
with the presence of lymphomas within the spinal column. 
 
The Atm -/- rat has proven to be a reliable model for some of the hematopoietic phenotypes 
observed in A-T, including the presence of aberrant T-cell development, as well as an 
increased frequency in development of lymphoid malignancies. To test whether delivery of 
wild type (WT) hematopoietic stem cell populations could provide therapeutic benefits, I 
performed BMT of WT bone marrow into Atm -/- rats. Importantly, I found bone marrow 
transplantations significantly delayed the onset of lymphoma within the recipients. 
 
 These data reveal that despite the fact that the rat recapitulates some aspect of A-T, such as 
lymphomagenesis, it does not reliably phenocopy the human disease in terms of cerebellar 
degeneration. Utilizing advanced imaging technologies such as those employed in this 
project, could provide a valuable model to investigate potential therapeutic approaches for 
treatment in A-T, such as BMT as well as human pluripotent stem cell based therapies. 
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1.1 Ataxia-Telangiectasia  
 
Ataxia telangiectasia (A-T) is an autosomal recessive disease named due to the presence of 
pronounced ataxia (a lack of voluntary control of motor movements) in early childhood and 
the presence of oculocutaneous telangiectasia (the presence of dialated blood vessels in the 
eyes) (Gatti, Boder et al., 1991). It has been estimated that 0.3% of the population in the 
United Kingdom are heterozygous carriers for a mutation in the Atm gene (Thompson, 
Duedal et al., 2005).  The median survival of patients suffering from A-T, resulting from two 
large cohort studies, were 19 and 25 years of age. However, there was a large range in both of 
these studies, attributable to inter-personal variation in the severity of several of the 
phenotypes associated with this disease.  (Crawford, Skolasky et al., 2006). The majority of 
A-T patients are wheel-chair bound before their early teens(Su and Swift, 2000) Mortality in 
most A-T patients is predominately a result of sinopulmonary infections or the development 
of neoplastic lymphoid malignancy (Su and Swift, 2000).  
 
 
 
 
Figure 1.1 Outline of Ataxia Telangiectasia phenotypes. Patients suffering from Ataxia 
Telangiectasia develop early childhood ataxia, neurodegeneration, immune deficiency, 
radiosensitivity, sterility, and have an increased susceptibility to cancer. Schematic from 
(McKinnon, 2004). 
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Individuals with A-T present with a variety of symptoms including early childhood ataxia, 
neurodegeneration, immune deficiency, radio-sensitivity, sterility, and an increased 
susceptibility to cancer (particularly lymphoid malignancy) (Figure 1.1) (McKinnon, 2004). 
As well as lymphoid malignancies, A-T patients also have an increased susceptibility for 
other forms of cancer including brain tumours and carcinomas (Hecht and Hecht, 1990) and 
heterozygous carriers of mutations in the Atm gene have been shown to have an increased 
risk of developing breast as well as possibly colon cancer (Renwick, Thompson et al., 2006).  
 
1.2 ATM and DNA Repair 
 
 
 
 
Figure 1.2 Structure of ATM and related proteins. The PIKK kinases involved in DNA 
repair ATM, ATR, and DNA-PK-cs contain the common protein motifs FAT 
(FRAP/ATM/TRAPP), FATC (FAT-C terminal), and a kinase domain (Modified from 
McKinnon, 2012). 
 
A-T is caused by a mutation in the ataxia telangiectasia mutated (ATM) gene located at 
chromosome 11q.22-23 (Savitsky, Bar-Shira et al., 1995). ATM is a high molecular weight 
protein (350 kDa) and is a member of the serine threonine kinase family Phosphatidylinositol 
3-kinase-related kinases (PIKK), which also includes A-T Mutated and Rad3 related (ATR) 
and DNA dependent protein kinase catalytic subunit (DNA PKcs), both of which play major 
roles in DNA damage response and have considerable sequence similarity with ATM 
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(Zakian, 1995, McKinnon, 2012).  All three  of these genes contain regions encoding for the 
protein motifs FAT (FRAP/ATM/TRAPP), FATC (FAT-C terminal), and a kinase domain 
(Figure 1.2) (McKinnon, 2012).  
 
ATM kinase plays a pivotal role in the cellular response to DNA double strand breaks 
(DSBs). Under normal conditions ATM is present in the cell in a dimer form, however in 
response to the presence of DNA DSBs ATM undergoes autophosphorylation at serine 1981, 
resulting in the dissociation of dimers to a monomeric form with active kinase activity 
(Bakkenist and Kastan, 2003). The dimer form of ATM is recruited to the site of DNA DSBs 
by the Mre11-Rad50-NBS1 proteins (MRN complex) via interaction with the C-terminal end 
of NBS1 (Kurz and Lees-Miller, 2004, Ambrose and Gatti, 2013). 
 
One of the first cellular phenotypes observed in cells obtained from individuals with A-T was  
an increased sensitivity to radiation (Taylor, Harnden et al., 1975). While the function of 
ATM in DNA DSB repair is certain to play a role in this, the increased radiosensitivity may 
also be the influenced by ATM’s  influence in multiple other mechanisms key to the cellular 
response to ionizing radiation, including responding to reactive oxygen species (ROS) (Guo, 
Kozlov et al., 2010) and cell cycle arrest (Abraham, 2001).    
 
1.3 ATM and Cell Cycle Arrest 
 
Cell cycle arrest is a key feature in cellular biology, which allows the cell time to repair 
damage resulting from cellular damage and in some cases undergo apoptosis in lieu of repair. 
ATM-deficient cells have been shown to display significant defects in the G1, S, and the G2 
cell cycle checkpoints (Abraham, 2001). ATMs influence on the G1 checkpoint is most likely 
a result of its role in the activation of p53 in response to DNA damage (Banin, Moyal et al., 
1998), as loss of p53 results in the abrogation of this checkpoint (North and Hainaut, 2000). 
In normal cells DNA damage will induce a decrease in DNA synthesis, however this decrease 
is dampened in ATM-deficient cells, giving rise to a phenotype known as radioresistant DNA 
synthesis (RDS) (Painter and Young, 1980). Cells with defects in ATM that are exposed to 
ionising radiation (IR) during the G1 or S phase show a protracted G2 cell cycle arrest, 
relative to normal cells, however cells exposed to IR during the G2 phase of the cell cycle 
show a relative decrease in the delay at this checkpoint (Scott, Spreadborough et al., 1994) 
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indicating a more prominent role for ATM in G2 cell cycle coordination in cells that receive 
damage during the G2 phase of the cell cycle. 
 
1.4 ATM and Reactive Oxygen Species 
 
All cells are continuously exposed to reactive oxygen species. This exposure can result from 
internal cellular processes as well as external physical sources such as UV and ionising 
radiation. The majority of ROS produced internally within the cell is produced from the 
respiratory chain, which occurs within mitochondria (Raha and Robinson, 2001). ROS are 
capable of inducing DNA DSBs, and therefore have the potential to activate ATM indirectly. 
As well as the potential for indirect activation, recent studies support that ROS are capable of 
directly activating ATM (Guo, Kozlov et al., 2010).  
 
An increased level of oxidative stress has been observed in A-T patients, as well as in Atm -/- 
mice (Barzilai, Rotman et al., 2002). Further, the presence of elevated levels of ROS has been 
associated with the presence on lymphoma development of a mouse model of A-T, as the 
anti-oxidative agent Tempol (4-hydroxytetramethy-L-piperidine-1-oxyl) was shown to inhibit 
lymphomagenesis in Atm -/- mice (Schubert, Erker et al., 2004). This inhibition in 
lymphomagenesis  is believed to be a result of the restoration of Ig class switch 
recombination (CSR) in B cells, as well as the restoration of normal V(D)J recombination 
and T cell development (Ito, Takubo et al., 2007). Further, the regulation of ROS by ATM 
has been shown to be required for the self-renewal of hematopoietic stem cells. 
 
Oxidative stress is likely to also contribute to the neurodegenerative phenotypes associated 
with A-T. ROS have been liked with the degeneration of Purkinje cells within the cerebellum 
in at least two studies utilizing animal models (Barlow, Dennery et al., 1999, Chen, Peng et 
al., 2003). Further, it has been shown that upon activation by oxidative stress p38 MAPK 
negatively regulates neural stem cell proliferation in Atm -/- mice (Kim and Wong, 2009). 
Given that the majority of the cells in the brain are post mitotic and that there is large 
metabolic requirement in these cells, an inability to regulate ROS levels may result in 
enhanced cell death in the brain.  This cell loss may be exacerbated by decreased neural stem 
cell proliferation in these patients resulting from p38 MAPK activation.   
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1.5 Neurological Phenotypes in A-T  
 
Neurodegeneration in A-T is progressive and spinocerebellar in nature, and usually becomes 
apparent in patients between 6 and 18 months of age. This degeneration generally results in 
patients being confined to a wheel chair by the age of 10. Patients with A-T also present with 
several hallmarks of cerebellar dysfunction, including an inability to co-ordinate voluntary 
muscle movements (dyssynergia), low muscle tone (muscular hypotonia), truncal swaying, 
and sudden falls (McKinnon, 2012).  
 
 
 
 
Figure 1.3 MRI imaging of an A-T patient. MRI studies of A-T patients have consistently 
observed prominent atrophy of the cerebellum (Tavani, Zimmerman et al., 2003).  
 
Several studies utilizing Magnetic resonance imaging (MRI) have consistently revealed 
prominent cerebellar atrophy in A-T patients (Figure 1.3) (Farina, Uggetti et al., 1994, 
Sardanelli, Parodi et al., 1995, Tavani, Zimmerman et al., 2003, Wallis, Griffiths et al., 2007). 
Histo-pathology has shown that this results primarily from a reduction in the number of 
granule cells, but that there is also a decrease in the number of Purkinje cells present in the 
cerebellum (Paula-Barbosa, Ruela et al., 1983). Along with Purkinje cell loss, histopathology 
of patient samples has shown that purkinje cells may also be present in regions other than the 
purkinje layer in the cerebellum of A-T patients (Bottini, Gatti et al., 2012). 
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As discussed above, it is likely that increased levels of ROS play a role in the 
neurodegeneration observed in A-T. However there are several other functions that may also 
contribute to degeneration such as increased levels of chromosome instability and aneuploidy 
(Iourov, Vorsanova et al., 2009) and altered apoptosis signalling (Tian, Yang et al., 2009). 
Further it is possible that the lack of functional ATM in patients with A-T negatively impacts 
brain development in these individuals. Experiments performed in mice have found high 
levels of ATM expression in the central nervous system (CNS) during early development 
(Soares, Morgan et al., 1998), consistent with observations of ATM expression throughout 
Xenopus development (Hensey, Robertson et al., 2000). A similar pattern has also been 
observed in developing human cerebellar neurons (Oka and Takashima, 1998). Further, it has 
been shown that ATM is required for the normal differentiation and development of adult 
neural progenitor cells (Allen, van Praag et al., 2001). 
 
1.6 Immunodeficiency in A-T Patients 
 
The most common immunological abnormalities observed in A-T patients are decreased or 
absent levels of the immunoglobulins IgA and IgG2, affecting 50-80% of A-T patients 
(Nowak-Wegrzyn, Crawford et al., 2004, Davies, 2009). Decreased levels of both T and B-
cells are also common amongst A-T patients (Staples, McDermott et al., 2008). However, 
normal natural killer (NK) numbers and cell activity has been observed in a cohort of A-T 
(Tsuge, Matsuoka et al., 1987). 
 
In spite of the immunological deficiencies described above, bacterial, viral, and opportunistic 
infections are fairly rare in patients with A-T (Nowak-Wegrzyn, Crawford et al., 2004). 
However, recurrent sino-pulmonary infections are common in A-T patients and often arise 
before neurological symptoms (Bott, Lebreton et al., 2007).  
 
1.7 ATM in V(D)J Recombination and T-cell development 
 
V(D)J recombination is a process in the development of T and B cells in which novel 
immunoglobulin and T cell receptor genes are assembled via a series of DNA breakage and 
re-joining events (Schatz and Swanson, 2011). ATM has been shown to be required for 
recombination between immunoglobulin switch regions (Reina-San-Martin et al., 2004). 
Further, a role for ATM has been proposed in DNA damage surveillance (Matei, Guidos et 
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al., 2006) as well as in sensing intermediates in V(D)J recombination (Perkins, Nair et al., 
2002). Further, ATM has also been shown to stabilize DNA double strand break complexes 
during V(D)J recombination (Bredemyer et al, 2006). As a result, A-T patients have a very 
high frequency of chromosomal aberrations on chromosomes 7 and 14,  which is 
approximately 40X higher than the general population (Aurias, Dutrillaux et al., 1980, Kojis, 
Gatti et al., 1991). Both A-T patients and Atm -/- mice have shown defects in the immune 
system associated with this process including thymic hypoplasia, Immunoglobulin (Ig) 
deficiency, and low numbers of T-cells (Barlow, Hirotsune et al., 1996, Xu, Ashley et al., 
1996).  
 
 
Figure 1.4 T-cell development in the thymus. T cell development proceeds from 
CD3+/CD4-/CD8- to CD3+/CD4+/CD8+ cells , and then finally to either CD3+/CD4+/CD8- 
or CD3+/CD4-/CD8+. It is during commitment to the CD3+/CD4+/CD8+ that T cell 
receptors first become evident. 
 
 
T-cell lymphopoiesis primarily occurs in the thymus and the generation of normal CD4+ and 
CD8+ cells is essential for a normally functioning immune system. The cell surface markers 
CD3, CD4, and CD8 are very useful in tracking the progression of T cell development, as 
cells progress from CD3+/CD4-/CD8- to CD3+/CD4+/CD8+ , and then finally to either 
CD3+/CD4+/CD8- or CD3+/CD4-/CD8+ (Anderson and Jenkinson, 2001, Zuniga-Pflucker, 
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2004) (Figure 1.4). It is prior to the CD3+/CD4+/CD8+ commitment that T-cells undergo 
V(D)J recombination and studies in mouse models have shown altered thymic T-cell 
development in Atm -/- mice, relative to their Atm +/+ counterparts with an increase in the 
frequency of CD3+/CD4+/CD8+ present in the thymus of these rats (Bagley, Cortes et al., 
2004, Amabile, Welner et al., 2013).  
 
As well as the role ATM plays in the development of T-cells it has also been shown to be key 
to the regulation of oxidative stress and self-renewal (Ito et al., 2004), as well as quiescence 
(Maryanovich et al., 2012) in haematopoietic stem cells. Therefore mutations in Atm may 
result in alterations far earlier in hematopoietic development that could potentially have 
downstream effects.  
 
1.8 ATM and Leukaemia  
 
As well as immunological dysfunction, leukemias are also common in patients with A-T. B 
and T-cell leukemias, as well as lymphomas, are present in an estimated 10-15% of A-T 
patients by early adulthood, with translocations involving regions of V(D)J recombination 
commonly observed in T-cell leukemias (Taylor et al., 1996). Defects in the ATM protein 
have been found in non A-T patients with B-cell chronic lymphocytic leukemias (CLL) 
(Stankovic et al., 1999) indicating its importance in mitigating the development of lymphoid 
malignancies. 
 
1.9 Animal Models of Ataxia Telangiectasia 
 
Several mouse Atm -/- models have been generated by disrupting the gene at different 
positions, which have resulted in the loss of expression of the ATM protein (Barlow, 
Hirotsune et al., 1996, Elson, Wang et al., 1996, Xu and Baltimore, 1996, Kuljis, Xu et al., 
1997, Herzog, Chong et al., 1998, Borghesani, Alt et al., 2000). These mice share some of the 
characteristics associated with A-T including immunological defects, radiation sensitivity, 
cell cycle defects, and chromosome instability. However, while these mouse models show 
some neurological abnormalities, neurodegeneration and cerebellar atrophy have not been 
observed (Lavin, 2013). More recently our group has produced a rat model which develops 
paralysis and shows a significant loss of motor neurons in the spinal cord, as well as the 
presence of microgliosis (Quek, Luff et al., 2015). Miniature pigs with gene targeted 
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mutations in the Atm gene have now been produced (Kim, Ahn et al., 2014), and a further 
porcine model has shown signs of cerebellar lesions which include altered cytoarchitecture 
and loss of Purkinje cells, as well as motor deficit phenotypes (Beraldi, Chan et al., 2015).  
 
1.10 Potential Therapies for Ataxia Telangiectasia 
 
In spite of numerous years of research there is still no curative treatment for A-T (Lavin, 
Gueven et al., 2007). This may be in part due to the complex nature of the ATM protein and 
the large number of interactions it has with other proteins. As a result of this, it is very 
difficult to elucidate specific mechanisms for targeting with therapeutics. It is possible that 
the phenotypes associated with A-T are a result of multiple mechanisms which may need to 
be addressed simultaneously. A novel approach that may help eliminate some of the 
phenotypes would be to integrate fully functional genetically normal tissues into A-T 
patients, through stem cell transplantations.  
 
As the most prominent neurodegenerative phenotypes observed, associated with A-T, involve 
the cerebellum, it seems logical that potential regenerative medicine approaches will have to 
focus on intra-cerebellar injection. While there has not been a great deal of research 
performed specifically on the injection of neural stem or progenitor cell populations into the 
cerebellum, some interesting experiments involving intracranial injections have been 
performed. These experiments have utilized both pluripotent, as well as adult neural stem and 
progenitor cell populations. Utilizing neural stem cells researchers have had success in 
treating some aspects of Parkinson’s disease in a mouse model via intracranial injection 
(Barberi et al., 2003; Toriumi et al., 2009). Further hESCs (Acharya, 2009), as well as hESC 
derived neural progenitors (Acharya et al., 2011), have been shown to ameliorate radiation 
induced cognitive decline upon transplantation into nude athymic rats, indicating these cells 
likely have the potential to functionally integrate in some situations. More relevantly hESC 
derived cerebellar-like cells have been injected intra-cranially into neonatal mice (Erceg et 
al., 2010). While no in vivo functional analysis was performed in these experiments, these 
cells (labelled with GFP) were shown to settle in the molecular layer of the cerebellum.  
 
Another potential strategy may be to use an adult stem/progenitor like cell for intra-cerebellar 
injection. One such cell type, with potential for clinical translation, is a multi-potent 
population known as olfactory ensheathing cells (OECs) or human olfactory derived 
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neurosphere forming cells (hONS). While no one has yet attempted injecting these cells into 
the cerebellum, behavioural improvement has been noted upon injection at the site of 
traumatic spinal cord injury in a rat model (Mackay-Sim and St John, 2011) indicating that 
they may have some potential for functional integration into the nervous system. However, a 
series of experiments has been performed in which the authors transplanted neural progenitor 
cells originating from other non-cerebellar regions of the brain and spinal cord (the 
telencephalic subventricular zone, medial ganglionic eminence, ventral mesencephalon and 
dorsal spinal cord), into the cerebellum of recipient rats (Rolando, Gribaudo et al., 2010). 
This study found that while all of the different types of donor cells were able to engraft in the 
recipient cerebellum, they failed to acquire cerebellar identities.  
 
The failure for functional integration of these adult type stem cells, upon transplantation into 
the cerebellum, may be due to multiple different factors. Perhaps the starting cell populations 
were not plastic enough to differentiate into cell types of the cerebellum. If this is the case, 
attempting injections with other adult stem cell populations may also prove fruitless, however 
pluripotent cells may prove useful as they are capable of producing a more primitive neural 
cell population. Another possibility is that failure to integrate is a result of not being present 
during development, and therefore not being exposed to the appropriate developmental niche. 
If the latter is true, than neither pluripotent nor adult progenitor cell injection are likely to 
alleviate A-T phenotypes associated with the cerebellum, as A-T is not diagnosed early in 
pregnancy. However, it seems that pluripotent stem cell transplantation may be capable of 
alleviating some of the neurodegeneration observed in this disease, given the success in other 
neurological disease models and their capacity to reside in the cerebellum. 
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1.10.1 Pluripotent Stem Cells  
 
 
 
 
Figure 1.5 Derivation of embryonic stem cells. ESCs derived from the inner cell mass of a 
4-5 day old embryo, at the blastocyst stage. At this stage the embryo is comprised of 
approximately 100 cells is an intermediate stage between morula and gastrula. 
 
 
Two different types of pluripotent stem cells currently exist with potentially utility therapy in 
individuals with A-T, human embryonic stem cells (hESCs) and induced pluripotent stem 
cells (iPSCs). Human embryonic stem cell lines, first derived in 1998 (Thompson et al., 
1998) are derived from the inner cell mass of a 4-5 day old embryo, at the blastocyst stage. At 
this stage the embryo is comprised of approximately 100 cells is an intermediate stage 
between morula and gastrula (Figure 1.5).  The most defining feature of these cells is their 
capacity to differentiate into cell types of all 3 germ layers, as well as to self-renew via 
asymmetrical division. More recently it was discovered that a pluripotent cell, with these 
same distinguishing characteristics, (iPSCs) could be generated by the forced expression of 
exogenous genes (Takahashi and Yamanaka, 2006). Recent advances in pluripotent stem cell 
biology have resulted in the directed differentiation of several cell and tissue types with 
potential utility in transplantation scenarios. In animal models, pluripotent cell derived 
products have proven useful for the treatment of several diseases including neonatal myelin 
disease (Brustle et al, 1999) Parkinson’s disease (Barberi et al., 2003; Toriumi et al., 2009), 
diabetes (Schroeder, 2006), liver failure (Soto-Gutierrez, 2006) and sickle cell anaemia 
(Hanna et al., 2007).  
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1.10.2 Bone Marrow Transplantation 
 
Bone marrow transplantation (BMT) was first shown to be capable of repopulating 
hematopoietic cells when it was used to rescue rats and guinea pigs that had received 
otherwise lethal doses of radiation (Jacobson, Simmons et al., 1951, Lorenz, Congdon et al., 
1952). The success of BMT transplantation, is premised on its ability to functionally integrate 
hematopoetic stem cells (HSCs) from healthy donors into recipients. It currently accounts for 
almost all of the clinical stem cell transplantations in current use. These therapies utilize 
HSCs (isolated or with other cells) from bone marrow and umbilical cords for transplantation 
(Daley, 2012).  
 
Very few bone marrow transplantations have been performed in A-T patients, and those that 
have been performed were performed in response to haematological disorder in these 
individuals. The first such transplantation was performed on a patient presenting with a 
Hyper IgM phenotype disorder, however not yet showing any clinical symptoms more 
commonly associated with A-T  (Ghosh, Schuster et al., 2012). BMT was successful in this 
patient with full lympho-hematopoietic reconstitution. However 8 months following 
transplantation the patient died due to encephalopathy and hepatic failure. Post mortem high-
throughput sequencing later revealed that there was a mutation in the A-T gene of this 
patient. More recently a 3 year old A-T patient with T-cell acute lymphoblastic leukaemia (T-
ALL), received an allogenic matched sibling transplantation which resulted in long term 
survival (Ussowicz, Musial et al., 2013).     
 
While little clinical data exists on BMT in humans, there have been at least two studies 
published using mouse models of A-T. The first such study (Bagley, Cortes et al., 2004) 
showed that transplantation of bone marrow from Atm +/+ mice to replace the bone marrow 
compartment of Atm -/- mice, was able to restore immune function and prevent lymphomas 
in these mice. A further study went on to show that the donor bone marrow derived cells 
migrated to the  bone marrow, blood, thymus, spleen and lung tissue of recipients, however 
were not found in the cerebellum or cerebrum (Amabile, Welner et al., 2013). 
 
Given the results in the mouse studies BMT seems to have therapeutic potential for the 
treatment of the haematological phenotypes associated with this disease. However, great care 
will have to be taken as these patients are likely to be more sensitive to treatments required to 
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ablate their current haematopoietic compart, and are also at an increased risk for graft vs host 
disease (Watson, McLaren et al., 1997).   
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2.0: Expression of Histocompatibility 2, Blastocyst 
(H2-Bl) in embryonic stem cells inhibits CD8+ T-cell 
activation but is not sufficient to facilitate graft 
tolerance 
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2.1 Introduction 
 
Several barriers to the utilization of pluripotent stem cell derived products in the treatment of 
disease, such as Ataxia Telangiectasia, currently exist. One such barrier is the potential for 
immune rejection of embryonic stem cell (ESC) derived tissues and cells after transplantation.  
Work with mouse embryonic stem cells (mESCs) proposed that low expression of major 
histocompatibility complex (MHC) class I, MHC class II and non-classical antigens 
(Magliocca, Held et al., 2006) as well as inhibition of T-cell maturation by transforming growth 
factor β (Koch, Geraldes et al., 2008) may result in immunological tolerance of these cells in 
transplantation settings. However, it was observed that while MHC class I molecules were 
expressed at very low levels in undifferentiated human embryonic stem cells (hESCs), there is 
an increase in expression upon differentiation and a dramatic elevation in response to IFN-
gamma which is secreted by multiple types of immune cells (Drukker, Katz et al., 2002) 
Evidently, additional strategies to avoid immunogenic rejection of embryonic stem cell derived 
products must be developed. There are four broad approaches that are currently being 
attempted; producing banks of human leukocyte antigen (HLA) matched pluripotent cells, 
immune suppression of recipients, production of gene corrected induced pluripotent stem (iPS) 
cells, and alteration of the intrinsic immunogenicity of the donor cells.  
 
Major histocompatibility complexes (HLA in humans), which normally act to present antigens 
to cells of the immune system, can themselves be recognized as antigens and induce an immune 
response (Bradley, Bolton et al., 2002). MHC molecules fall into three broad classes (denoted 
MHC class I, II, and III). Amongst these MHC class I molecules (which include HLA-A, B, C, 
E, F, G in humans) were found to be the primary causative agents in the induction of an immune 
response following hESC transplantation (Deuse, Seifert et al., 2011). For organ 
transplantation, matching of HLA antigens is often used and has been shown to be a good 
indicator of graft acceptance. 
 
It has been proposed that producing a bank of iPSCs from selected HLA-typed volunteers may 
similarly avoid immune rejection and facilitate transplantation. It was calculated that a bank of 
150 iPSC cell lines could provide matched stem cells for 93% of the U.K. population (Taylor, 
Peacock et al., 2012). While these predictions are encouraging, it remains to be determined 
how effective HLA matching will be for successful transplantation and long term engraftment, 
given that even minor histocompatibility complexes (mH), peptides carrying unique 
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polymorphisms, appear to be sufficient to induce acute rejection of mESCs upon allogenic 
transplantation (Robertson, Brook et al., 2007).  
 
Another option, also employed in organ transplantation, is the suppression of the immune 
response. Experiments with the clinically available immunosuppressant drugs Sirolimus, 
mycophenolate mofetil, and Tacrolimus were only able to partially mitigate the immune 
response following injection of hESCs into an immune competent mouse, and these xenogenic 
grafts were rejected within 28 days (Swijnenburg, Schrepfer et al., 2008). Continuous treatment 
with cyclosporine A on the other hand does permit persistence and long-term engraftment of 
human ES and iPSC derived cell types in immuno-competent recipients (Buhnemann, Scholz 
et al., 2006, Caspi, Huber et al., 2007, Lamba, Karl et al., 2008, Lamba, Gust et al., 2009, 
Toriumi, Yoshikawa et al., 2009). However, such continuous immune suppression would leave 
a recipient vulnerable to opportunistic infection, and is therefore not a favourable approach. 
Alternative immune suppression strategies for pluripotent stem cell based therapies, using a 
leukocyte co-stimulatory blockade (Pearl, Lee et al., 2011), have meanwhile been developed. 
While administration of costimulatory blocking agents (anti-CD40L, anti-LFA and CTLA-4-
Ig) during the first 6 days following injection facilitated engraftment of pluripotent (mESC, 
hESC, miPSC, hiPSC) as well as mouse bone marrow mononuclear cells for up to ~50-70 days 
post injection, it remains to be determined how this approach affects the long term immune 
competence of the recipient mice. Similar to traditional immune suppression, these treatments 
may leave patients vulnerable to opportunistic infection.  
 
An attractive solution for the evasion of immunogenicity of stem cell transplantation is to 
produce patient specific induced pluripotent stem cells (iPSCs). While early reports questioned 
the immunogenicity of iPSC (Zhao, Zhang et al., 2011), this was subsequently refuted (Guha, 
Morgan et al., 2013), and next shown to be dependent on the specific cell type that is delivered 
(Zhao, Zhang et al., 2015). While it is not unlikely that iPSCs will ultimately provide a source 
of tissues and cells for autologous transplantation, enabling such iPSC-based cellular therapies 
will require cheap plug-and-play type generation of iPSCs under xeno-free GMP compliant 
conditions in hospital settings and will require rapidly obtainable, robust safety criteria.  
 
It is clear that human pluripotent stem cell based therapies would greatly benefit from the 
production of a thoroughly characterised “universal donor ES-cell” that can be accepted by the 
immune system of any patient. The production of such a cell line was pioneered by Deusse et 
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al by knocking down HLA class I in hESCs (Deuse, Seifert et al., 2011). While these cells 
certainly proved to be less immunogenic than their wild type counterpart, approximately 50% 
of grafts were still rejected from immune competent mice. 
 
Here I have attempted to take advantage of the mouse homologue of the immunotolerogenic 
molecule HLA-G (known as H2-Bl) to produce pluripotent cell lines compatible with allogenic 
and possibly xenogenic transplantation. Our decision to test this molecule was based on its 
expression on the maternal foetal interface of trophoblast cells (Kovats, Main et al., 1990), 
where it plays a  key role in  maternal immunotolerance of the foetus, and protects trophoblasts 
from maternal natural killer (NK) cell lysis (Rouas-Freiss, Goncalves et al., 1997). It was 
further shown that this protection was transferable to other cells, as cytotrophoblasts transfected 
with either HLA-G1 or HLA-G2 cDNA, were also protected from NK cell induced cell lysis 
(Rouas-Freiss, Marchal et al., 1997). As graft rejection is for a large part mediated by host T-
cells recognizing polymorphisms in MHCs and mHs (Walsh, Strom et al., 2004), a role for 
HLA-G in T-cell mediated immune suppression was inferred. Indeed, HLA-G inhibits CD8+ 
cytotoxic T lymphocytes (CTL) (Le Gal, Riteau et al., 1999), CD4+ T-Cell proliferation 
(Riteau, Menier et al., 1999), and can induce immunosuppressive CD4+ T regulatory cells 
(LeMaoult, Krawice-Radanne et al., 2004). Furthermore, HLA-G also inhibits the maturation 
of antigen presenting dendritic cells (Ristich, Liang et al., 2005). The role of HLA-G in 
mediating immune tolerance further extends well beyond pregnancy. Detection of soluble 
HLA-G in patients receiving heart (Lila, Amrein et al., 2002), liver(Zarkhin, Talisetti et al., 
2010), or kidney (Creput, Durrbach et al., 2003), transplants is associated with enhanced graft 
acceptance and  human muscle cell lines transiently transfected with HLA-G1 and HLA-G5 
expression constructs elicit reduced human cytotoxic T-cells responses and  undergo less NK 
cell induced lysis (Wiendl, Mitsdoerffer et al., 2003). Based on the ability of HLA-G to inhibit 
multiple mechanisms associated with immune rejection, I was interested to find out whether 
expression of different H2-Bl isoforms could facilitate transplantation of human and mouse 
ES-cells in immune competent mice.  
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2.2 Materials and Methods 
 
2.2.1 hESC Cell Culture Conditions 
 
hESCs were cultured in knock out serum replacement (KSR) hESC culture medium (80% 
DMEM F12 (GIBCO), 20% KnockOut-Serum replacement (GIBCO), 2 mM L-glutamine 
(GIBCO), 1% non-essential amino acids (NEAA) (GIBCO), 0.1 mM 2-mercaptoethanol 
100ng/ml basic fibroblast growth factor) (Invitrogen) at 37°C at 5% CO2 and at high humidity. 
Cells were cultured in feeder-free conditions on Matrigel™ (BD) in MEF conditioned hESC 
culture medium. Cells were passaged with collagenase IV (1mg/ml) (Stem Cell Technologies) 
before replating at a seeding ratio of between 1:2 and 1:6. hESC media was replaced daily and 
cells were split at approximately 80% confluence on days 6-7. 
 
2.2.2 mESC Culture Conditions 
 
mESCs were grown in knock out serum (KSR) replacement ESC culture medium (80% DMEM 
F12 (GIBCO), 20% KnockOut-Serum replacement (GIBCO), 2 mM L-glutamine (GIBCO), 
1% non-essential amino acids (NEAA) (GIBCO), 0.1 mM 2-mercaptoethanol 1000 U/ml 
murine leukemia inhibitory factor (mLIF) (Invitrogen) at 37°C at 5% CO2 and at high humidity. 
Cells were maintained on mouse embryonic fibroblasts (MEFs) at a density of 0.8 x 105 
cells/cm2. For experimentation, cells were cultured in feeder-free conditions on Matrigel™ 
(BD) in MEF conditioned ESC culture medium. Cells were passaged using trypsin to dissociate 
cells into small clumps before replating at a seeding ratio of between 1:2 and 1:6. ESC media 
was replaced daily and cells were split at approximately 70% confluence on days 2-3. 
 
2.2.3 Generation of H2-Bl Expressing Cells 
 
pLenti plasmids containing one of the H2-Bl isoforms (a soluble form from C57BL/6 mice and 
a membrane bound form from 129/SvJ) or a GFP control were produced using the Gateway® 
cloning system. An HA tag sequence was introduced in the 3’ Primer to encode the HA tage at 
the C-terminus. 293FT cells were transfected with the lentiviral vector DNA, PMDg, PRSV-
Rev, and pVSVg using Lipofectamine 2000 (all from Invitrogen) and virus was collected 36 
hours post-transfection. This virus was then used to transduce desired cells for 24 hours in 
presence of 7μg/ml polybrene (Sigma). Feeder free cultured Cells were expanded for 5 days 
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after which they were selected using 2μg/ml puromycin. Resistant colonies were picked after 
4 days, expanded and cryopreserved. 
 
2.2.4 Western Blotting 
 
Cells were washed twice with 1× PBS and then lysed with 5× loading buffer (130mM Tris pH 
6.8, 4% SDS, 0.02% Bromophenol blue, 20% glycerol, 100mM DTT) containing 10% 
PhosSTOP phosphatase inhibitor (Roche). They were subsequently homogenized using a 30G 
needle and heated to 80°C for 10 mins. Proteins were resolved using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). The iBlot® Dry Blotting System 
(Invitrogen) was used to transfer proteins to a PVDF membrane. Blots were submerged in 
blocking buffer (Tris-buffered saline with 0.01% Tween-20 (TBST) and 5% Bovine serum 
albumin (BSA)) at room temperature (~21°C) for 2 hours.  Blots were then then probed with 
appropriate antibodies diluted in blocking buffer at 4°C over-night with gentle agitation. Probes 
were then washed three times for 15 minutes each, before submersion in appropriate secondary 
antibodies diluted in blocking buffer for one hour at room temperature. Blots were then washed 
as before and analysed using Pierce ECL Western Blotting detection kit according to 
manufacturer’s recommendation (Thermo Scientific) on the V3-Western Workflow (Bio-Rad) 
for a densitometric representation. The images were respectively analyzed using either One-
Rad (Bio-Rad) or Image Lab (Bio-Rad).  
 
2.2.5 Immunostaining 
 
For immunostaining cells were washed in PBS and fixed in 4% paraformaldehyde for 15 
minutes at 4°C. For nuclear staining samples were permeabilized in 0.1% Triton X-100 at room 
temperature for 10 minutes, before blocking with 10% goat serum and incubation with the 
relevant antibodies overnight at 4°C. Antibodies and dilutions used were OCT4 (Millipore) 
[1:1000], NANOG (Millipore) [1:400], and HA (Cell Signalling) [1:1000]. Following washing 
with PBS (3 times for 5 min at room temperature) secondary antibodies goat anti-mouse IgG1, 
goat anti-mouse IgG2B, goat anti-mouse IgM and Donkey anti-rabbit IgG (Alexa fluor) 
[1:1000] were used. Nuclei were stained with DAPI. This preparation minus the addition of 
primary antibody was used to confirm specificity of staining.  
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2.2.6 In Vivo T Cell Activation Assay 
 
1 million ESCs were delivered via tail vein injection into NOD.Rag1-/-.IL-2rγc-/- (NRG) mice 
(Jax Laboratories). 24 hours following injections of ESCs 5 million splenocytes which  
had been incubated for 10 min in 1 µM violet proliferation dye 450 (VPD450) (Thermo Scientific) 
were injected per animal. At day 7, splenocytes were harvested for flow cytometry. 
For flow cytometry, cells were incubated on ice with conjugated anti-CD8 antibodies with 1 
mg/ml propidium iodide (Calbiochem, San Diego, CA). Flow cytometric analysis was 
performed on a FACSCalibur (BD Biosciences, North Ryde, NSW, Australia) with standard 
optics configuration (405 nm violet laser, 488 nm blue laser, 633 nm red laser) with CellQuest 
version 3.1F software (BD Biosciences, San Jose, CA). Post-acquisition data analysis was 
performed with FlowJo software (Treestar, Ashland, OR, USA). 
 
2.2.7 Teratoma Formation 
 
hESCs collected by collagenase IV treatment and mESCs were collected by trypsin treatment. 
One million cells, resuspended in 50 μL DMEM/F12 supplemented with 50% BD Matrigel™, 
were injected into hind limb muscles of Methoxyflurane anaesthetised 6-week-old SCID or 
CB7BL/6 mice (from the Animal Resource Centre (ARC) in Western Australia). After eight to 
ten weeks, teratomas were dissected and fixed in 4% paraformaldehyde. Samples were 
embedded in paraffin, stained with haematoxylin and eosin and examined for the presence of 
representatives of the three germlayers. All mouse procedures were conducted under local 
ethical guidelines and after gaining permission from the local animal ethics committee 
(University of Queensland, QLD, Australia).  
 
2.2.8 Statistics 
 
Data represent mean ± S.D of the number (n) of independent experiments unless indicated 
otherwise. Statistical significance has been calculated by a two-way ANOVA with Bonferroni 
post-tests to compare replicate means between the indicated groups for all experiments or via 
student’s T-test where appropriate. 
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2.3 Results 
 
The human HLA-G gene and its mouse homologue H2-Bl are composed of 8 exons which can 
be alternatively spliced to produce several different isoforms. Exon 1 codes for the leader 
fragment, exon 2, 3, and 4 encode the 3 extracellular domains (α1, α2, and α3 respectively), 
exon 5 encodes the transmembrane domain and exon 6 encodes the cytoplasmic tail. Exon 7 is 
not transcribed and exon 8 is the 3’ UTR region (Gonzalez, Rebmann et al., 2012). Seven 
different isoforms of human HLA-G are currently known and the mouse homolog (H2-Bl) can 
be alternatively spliced into at least 3 different isoforms (Guidry and Stroynowski, 2005, 
Amiot, Vu et al., 2015). Here I have used the mouse isoforms most similar to human HLA- 
 
G1 (referred to as Membrane Bound (M)) and most similar to human HLA-G5 (referred to as  
Soluble (S)) (Figure 2.1A). The human ESC line ENVY (Figure 2.1B), previously shown to 
constitutively express high levels of GFP throughout differentiation (Costa, Dottori et al., 
2005), and the mouse ESC line R1 (Figure 2.1C) were stably transduced with lentivirus 
encoding either the membrane bound (MB) or soluble (S) form of the mouse H2-Bl protein, 
driven by the PGK reporter, and containing a puromycin resistance gene cassette. The H2-Bl 
sequences were modified to include a C-terminal HA tag allowing for identification of the 
protein, as no antibody currently exists for H2-Bl. The HA tag of membrane bound protein was 
detectable by immunofluorescence (Figure 2.1D) and both forms were detectable by western 
blot analysis (Figure 2.1E) in both hESC and mESC, indicating that transduction successfully 
produced mESC and hESC that constitutively express the membrane bound or soluble form of 
the H2-Bl protein. 
 
The transduced murine and human ES cell lines maintained their pluripotency following 
puromycin selection as indicated by robust staining for the nuclear markers of pluripotency 
Nanog (Figure 2.2A) and Oct4 (Figure 2.2B,C).  
 
To verify that the soluble H2-Bl (S-H2Bl) and membrane bound H2-Bl (M-H2Bl) expressing 
human and mouse cell lines were truly pluripotent I next performed teratoma assays in 
nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. Following 
intramuscular injection into immune compromised NOD/SCID mice, all hESC and mESC cell 
lines formed teratomas containing tissues of all three germ layers (endoderm, mesoderm, and 
ectoderm). (Figure 2.3; Supplemental Figure 1). 
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I next performed G-band karyotype analyses on the parental cell lines (Supplemental Figure 2) 
and discovered that transduced ENVY hESC cells exhibited a normal karyotype with the 
exception of a missing X chromosome 45,X-X. As this karyotype was consistent across all 
cells analysed, and did not alter the expression of HLA or the capacity to differentiate into all 
three germ layers, it was concluded that the loss of the chromosome in these cells would not 
interfere with our ability to assess the effect of H2-Bl expression on immune mediated cell 
rejection. 
 
 
Figure 2.1 Generation of H2-Bl expressing mESC and hESC cell lines. (A) Schematic 
representation of the membrane bound (MB) and soluble (S) isoforms of H2-Bl used in these 
experiments.  (B) Phase contrast image of the hESC line ENVY. (C) Phase contrast image of 
the mESC line R1. (D) The HA tag on of membrane bound H2-Bl molecule was detectable in 
both ES cell lines as shown by immunofluorescence. (E) Presence of both isoforms of the H2-
Bl protein as detected by western blotting. 
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Figure 2.2 H2-Bl transduced mESCs and hESCs express pluripotency markers. (A) All 
transduced hESC lines exhibit expression of the nuclear pluripotency marker Nanog. The 
nuclear pluripotency marker Oct-4 was also detected in transduced mouse (B) and human (C) 
ESC lines.  
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Figure 2.3 H2-Bl transduced mES and hESC form teratomas in NOD-SCID mice. H&E 
stained images of paraffin embedded teratomas from parental lines show the presence of tissues 
from all three germ layers. 
 
I next assessed whether M-H2Bl and S-H2Bl expression altered the proliferation or survival of 
hESCs and mESCs, as this could affect the capacity of the cells to proliferate in an in vivo 
environment and therefore the immunogenicity of the cells. I detected no significant difference 
in either the growth rate (Figure 2.4 A, B) or viability (Figure 2.4 C,D) between any of the 
transduced hESCs and mESCs relative to each other or their parental cell lines.  
 
Previous studies have found CD8+ T-cells to play a major role in the rejection of pluripotent 
stem cell derived cells and tissues. (Swijnenburg, Schrepfer et al., 2008, Swijnenburg, 
Schrepfer et al., 2008, Pearl, Lee et al., 2011). As such, I chose to assess the capacity of the 
H2-Bl molecule to inhibit ES cell induced CD8+ T-cell proliferation in an in vivo situation. 
Parental as well as S-H2Bl and M-H2Bl transduced ESC lines were injected via tail vein into 
NOD.Rag1-/-.IL-2rγc-/- (NRG) mice. 24 hours following injections MACS bead sorted CD8+ 
cells (isolated from the spleen of BALB/c mice) were stained with violet proliferation dye 
450 (VPD450) and injected via tail vein injection (Figure2.5A). 
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Figure 2.4 Cell growth kinetics and viability of transduced cell lines. (A) All transduced 
hESC lines showed similar cell growth rate regardless of the presence of either H2-Bl molecule. 
(B) No significant difference was observed in the growth rate kinetics of any of the mESC 
lines. The percentage of viable cells detected in culture was not significantly altered in any of 
the hESC lines (C) or mESC lines (D) expressing either H2-Bl isoform relative to controls. 
 
The number of CD8+ T cell divisions were next assessed at day 7 following ESC injections 
(Figure 2.5B). The median fluorescence intensity of the VDP450-labelled T cells was 
significantly lower in mice that received untransduced hESCs when compared to mice that 
received hESCs transduced with either S-H2Bl or MB-H2Bl (Fig 5C); I also observed a 
significant increase in the percentage of cells which had undergone ≥1, ≥2, or ≥3 cellular 
divisions (Figure 2.5 D-F) in mice receiving the parental controls, indicating that both H2-Bl 
isoforms are capable of inhibiting CD8+ T-cell proliferation. 
 
To test whether M-H2Bl and/or S-H2BL expression was sufficient to evade the immune 
response of immune competent animals, all human and mouse ESC lines were injected 
intramuscularly into both NOD/SCID and C57BL/6 mice. While all of the cell lines were  
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Figure 2.5 H2-Bl S and MB inhibit CD8+ T cell proliferation. (A) Schematic representation 
of experiments. (B) Representative flow cytometry histograms of VPD450 in CD8+ cells from 
the spleen of recipients. (C) CD8+ splenocyets injected in recipients containing ES cells 
expressing either S-H2Bl or MB-H2Bl showed a decrease in the median florescence intensity 
of VPD. (D-F) CD8+ cell proliferation was significantly lower in when injected into mice 
containing ES cells expressing either S-H2Bl or MB-H2Bl relative to control ES cells, and was 
similar to that seen in mice that had not received ES cell injections. (n=3, * p<0.05, ** p<0.01, 
*** p<0.001). Horizontal bars represent average and standard deviation. 
 
 
28 
 
capable of forming at least one teratoma in the NOD/SCID recipients, no teratomas were 
observed when any of the cell lines were injected into wild type C57BL/6 mice (Figure 2.6), 
indicating that H2-Bl expression did not facilitate transplantation into immune competent 
animals. To assess whether this was perhaps related to insufficient expression levels of M-
H2Bl or S-HSBl I next reselected all transduced mouse and human ES cell lines with a higher 
concentration of puromycin in order to re-establish lines with higher expression levels. 
However, following a second round of injections all of the H2-Bl transduced lines again failed 
to generate teratomas in C57BL/6 mice, despite increased M-H2Bl or S-H2Bl expression, 
while producing multilineage teratomas in NOD/SCID recipients.   
 
 
 
Figure 2.6 Teratoma formation in immune compromised and immune competent mice. 
Teratoma formation was observed in all Nonobese diabetic/severe combined 
immunodeficiency (NOD/SCID) injected with ES cells upon intramuscular injection of 1×106 
ES cells. No teratoma formation was observed in any C57BL/6 mice. 
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2.4 Discussion 
 
The generation of an ESC donor cell line capable of being accepted by all recipients would 
greatly improve the potential of hESC and iPSC based regenerative medicine and help to 
facilitate the testing of cellular products in small and large animal species. Our data show that 
expression of the soluble and membrane bound forms of H2-Bl does not interfere with 
proliferation, viability or differentiation capacity of mouse or human ES cells, while it was 
capable of inhibiting CD8+ splenocyte proliferation responses in vivo. However, this by itself 
proved insufficient to permit xenogenic or allogenic teratoma formation in immune competent 
mice. As short term teratoma formation has been shown to be permitted in immunocompetent 
mice in situations of isogenic iPS transplantation (Guha, Morgan et al., 2013), as well as immune 
suppression (Pearl, Lee et al., 2011), I believe this to be a valid assay for the characterization 
of potential immune suppression regimens.  
 
 
Although I detected robust expression of both the soluble and membrane bound forms of H2-
Bl in our ES cell lines, and tested clones with even higher expression, it is possible that 
expression levels were still not sufficient to overcome T-cell mediated lysis. I further note that 
in the NRG recipient mouse model used in our T-cell activation assay there was a relatively 
high background proliferation rate in CD8+ cells, likely due to the homeostatic proliferation 
which is known to occur in response to signals of lymphopenia in these recipient animals. As 
such, the observed inhibition of CD8+ division may not have been solely due to T cell 
activation associated with immune rejection. However, given previous publications involving 
the human HLA-G protein, our results are consistent with the inhibition of a cytotoxic T 
lymphocyte response (Le Gal, Riteau et al., 1999). 
 
An important immunological difference between NOD/SCID and C57BL/6 mice is the lack of 
detectable haemolytic complement in NOD/SCID mice (Shultz, Schweitzer et al., 1995). Given 
that complement plays a major role in early and hyper-acute graft rejection (Lee and Christie, 
2009) and that there is no known role for HLA-G/H2-Bl with regards to inhibition of the 
complement pathway, it is possible that the rejection of our transplantations into immune 
competent C57BL/6 mice was facilitated via the complement pathway. As such, future 
attempts at utilizing H2-Bl may benefit from the addition of complement inhibitors such as 
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sCR1, CR2-Crry, or CR2-fH during transplantation, as they have been shown to be useful in 
previous transplantation models (Pruitt, Bollinger et al., 1996, Atkinson, He et al., 2010).     
 
 
In conclusion, similar to knock-down of HLA class I, expression of H2-Bl in ESCs is not 
sufficient to fully protect grafts from immune mediated rejection. It will be interesting to assess 
whether HLA-G/H2-Bl expression can play a role in overcoming the immune rejection of 
iPSCs and whether the expression of H2-Bl in combination with the deletion of MHC can be 
effective. It is also worthwhile investigating whether concurrent inhibition of complement 
mediated immunity is also required. In our opinion the quest for such a universal donor line, 
although at present elusive, is a viable and worthwhile exercise in light of the enormous 
scientific and medical benefits that such a line would bring to regenerative medicine 
approaches.   
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2.6 Supplementary 
 
 
Supplemental Figure 1 Teratoma formation. All cell lines were capable of forming 
teratomas comprised of ectoderm, mesoderm and endoderm lineages. 
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Supplemental Figure 2 G-banding of cell lines. ENVY hESC based cell lines (A) exhibit a 
normal karyotype with the exception of a missing X chromosome 45,X-X. (B) All R1 mESC 
lines exhibit a normal karyotype 40,XY 
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3.0 Radiological Imaging of a Rat Model of Ataxia 
Telangiectasia 
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3.1 Introduction 
 
While multiple mouse models of A-T currently exist and recapitulate some of the phenotypes 
attributed to the human disease, the most prominent neurodegenerative phenotypes, 
associated with the prominent ataxia in humans, have not been observed in these animals 
(Lavin, 2013). As such, our research group has produced a gene knock-out model in the rat, 
utilizing Zinc Finger Nuclease technology. This rodent model is the first to show neurological 
defects including dilated blood vessels in the eyes, microgliosis and the development of hind 
limb paralysis in approximately 50% of rats. Further, these animals share a predisposition 
towards hematological malignancy with human A-T patients, as lymphomas were detected by 
histological examination in greater than 90% of these animals (Quek, Luff et al., 2015).  
 
Small animal imaging modalities were utilized to try to better understand the phenotypic 
abnormalities observed in a knockout (KO) rat model of A-T. Structural MRI studies were 
performed on this rat model covering the whole brain, as well as the region of the spine 
relevant to the paralysis observed in these animals. Given the previously observed differences 
in microglial activation observed in the brain of this rat model, the tracer TSPO which is 
specific to activated microglia in the brain, was also used in multimodality PET-MRI, 
autoradiography and Gamma counter experiments.  
 
3.1.1 Radiological Imaging 
 
Various nuclear medicine methods now exist for imaging anatomical structures, as well as 
biochemical features in humans and animal models. Such imaging modalities include 
standard x-ray, dual energy x-ray absorptiometry (DEXA), computed tomography (CT), 
ultrasound (US), Positron Emission Tomography (PET), and magnetic resonance imaging 
(MRI). While quantifiable images can be produced from all of these imaging modalities, 
accurate spatially resolved data can only be produced from CT and MRI imaging. As a result, 
MRI and CT imaging can both be used to produce 3D quantifiable images, with CT scans 
being preferable for hard tissues such as bone and MRI being preferable for softer tissues 
such as the brain and nervous tissue. Due to PET imaging’s ability to detect particular 
molecular structures it has become a powerful tool, particularly when used in conjunction 
with MRI or CT imaging. A major benefit to utilizing radiological imaging techniques in 
animal model based research is that the imaging is performed on live animals, allowing for 
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longitudinal studies in the same animals, as well as minimizing effects associated with the 
extraction of tissues and cells. Further, results from animal studies with potential for 
improving diagnosis and treatment regimens for disease have relatively direct clinical 
translatability.  
 
3.1.2 Radiological Imaging and Ataxia Telangiectasia 
 
Amongst imaging modalities MRI has been the preferred modality, when imaging A-T 
patients or animal models with a mutation in the ATM gene, due to its lack of radiation, high 
soft tissue contrast, and high spacial resolution. However, some early research utilizing CT 
scans was performed on A-T in which they were able to detect cerebellar atrophy amongst 
these patients (Wong, Yu et al., 1987). However a later paper directly comparing CT with 
MRI imaging for the assessment of A-T patients (Farina, Uggetti et al., 1994) noted that MRI 
was the preferential modality due to its ability to better visualize the posterior fossa structures 
in these patients, alongside the lack of radiation required for MRI imaging. 
 
There have been several minor observations noted in MRI studies on A-T patients however 
the most prominent and consistent observation amongst these studies is the presence of 
prominent atrophy in cerebellum (Farina, Uggetti et al., 1994, Sardanelli, Parodi et al., 1995, 
Tavani, Zimmerman et al., 2003, Wallis, Griffiths et al., 2007), as well as an enlargement of 
the fourth ventricle and cisterna magna (Sardanelli, Parodi et al., 1995). The degree of this 
cerebellar atrophy has been correlated with age as well as clinical severity, with older patients 
having more severe atrophy, as well as a greater degree of atrophy (Tavani, Zimmerman et 
al., 2003). These observations are consistent with post mortem pathology reports from the 
literature (De Leon, Grover et al., 1976, Verhagen, Martin et al., 2012). Further, more recent 
study utilizing diffusion tractography has found white matter degeneration along the entire 
lengths of multiple motor circuits, indicating that ATM impacts multiple other motor circuits, 
as well as the cerebellum (Sahama, Sinclair et al., 2015).  
 
As well as the aforementioned structural changes in the brain, some changes have been 
observed in the spinal column of A-T patients. While the focus of most MRI research in A-T 
patients has been on structural and physiological changes in the brain, a recent study has 
looked at structural changes in the spinal column.  The predominant structural aberration 
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observed in this study was anterior horn cell degeneration, which was predominantly found in 
the lumbar region of the spinal column (Verhagen, Martin et al., 2012). 
 
3.1.3 MRI Basics 
 
The signal that we are able visualize when performing MRI is derived from the nuclear 
magnetic resonance (NMR) of the Hydrogen (1H) nuclei. While a number of other nuclei 
present in human and animal tissues (e.g. 13C, 15N, 31P) also exhibit the ability to absorb and 
re-emit electromagnetic radiation while in a magnetic field, 1H is far more abundant in 
relevant human and animal tissues, due to the large percentage of H2O found in these tissues 
(Brown and Semelka, 2003). 
Individual 1H nuclei possess a magnetic moment moving parallel to their axis (Figure 3.1A). 
In the absence of a strong external magnetic field the axis of the hydrogen atoms are 
randomly aligned with tissue (Figure 3.1B). In a typical MRI experiment a main magnetic 
field (B0) is applied, thus partially aligning the hydrogen atoms both parallel (a low energy 
state) and anti-parallel (a high energy state) to the main magnetic field, giving the sample a 
net magnetization vector (M0) parallel to B0 (Figure 3.1C).  
 
 
Figure 3.1 Hydrogen ion movement in MRI. (A) Individual 1H nuclei possess a magnetic 
moment moving parallel to their axis. (B) In the absence of a strong external magnetic field 
the axis of the hydrogen atoms are randomly aligned with tissue. (C) A main magnetic field 
(B0) is applied, thus partially aligning the hydrogen atoms both parallel (a low energy state) 
and anti-parallel (a high energy state) to the main magnetic field, giving the sample a net 
magnetization vector (M0) parallel to B0. Adapted from (Brown and Semelka, 2003).  
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Hydrogen ions within a magnetic field will precess about the axis of the B0 field (Figure 3.2) 
at a frequency defined by the Lamor equation: 
 
 ω0 = γB0/2π 
 
where ω0 is the Lamor frequency  measured in Megahertz (MHz), γ is a constant for each 
nucleus known as the gyromagnetic ratio and B0 is the magnetic field strength measured in 
Tesla (T). During a typical MRI experiments, an external radiofrequency (RF) wave with the 
same frequency as the Lamor frequency of the spins is next applied to the sample. This 
external frequency causes some of the spins to shift from a low energy state (parallel to B0) to 
a high energy state (perpendicular to B0). When this occurs the Lamor precession of the spins 
produces a voltage measurable by the RF coil, which is measured as the MR signal.  
 
 
 
Figure 3.2 Lamor movement around the axis. Hyrodgen ions precess around the axis of the 
B0 field at a frequency that can be defined utilizing the Lamor equation. When an 
electromagnetic force at the Lamor frequency is applied the sum of the spins shift from a low 
energy position to a high energy position, moving towards a position perpendicular to B0, a 
movement towards the x component. 
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The RF signal is then shut off and the spins begin to recover to their previous state. Different 
tissues relax at different rates after the RF signal is turned off. There are two ways of 
measuring the time it takes for the protons to fully relax. The time it takes for the magnetic 
vector to return to its resting state is known as T1 relaxation. The time it takes for the axial 
spin to return to its resting state is known as T2 relaxation. 
 
3.1.4 PET Basics 
 
 
 
Figure 3.3 Schematic representation of small animal PET imaging. (James and Gambhir, 
2012) 
 
PET is a nuclear medicine imaging technique that can observe functional processes which 
occur in living patients or animals in three dimensions. It utilizes the detection of γ rays 
which are the indirect result of the decay of certain radioactive isotopes. The half-life (t1/2) is 
a key consideration when choosing isotopes for imaging, as it effects both the availability of 
isotopes for experiments, as well as parameters of experimental design such as the length of 
acquisition.  Some of the more common radioactive isotypes utilized in PET include 18F (t1/2 
= 109.8 mins), 68Ga (t1/2 = 67.8 mins), 11C (t1/2 = 20.3 mins) and 64Cu (t1/2 = 12.7 hrs). 
When nuclei in one of these radioactive isotopes starts to decay, as a result of a surplus in the 
number of protons, positron (β +) emission occurs. This results in the destabilization of the 
nucleus. In order to restabilise the nucleus of the atom a proton is converted in to a neutron, a 
positron and a neutrino. When this occurs in the commonly utilized 18F isotope this results in 
the formation of a stable 18O isotope, as well as the emission of the positron and the neutrino. 
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As the released positron is highly unstable, it will then quickly lose its kinetic energy and will 
annihilate with an electron from a nearby nuclei in the surrounding tissue. This annihilation 
event results in the release of two 511 keV photons travelling in opposite directions 180° to 
each other. It is these photons that are detected by the rings of the PET detector (Figure 3.3). 
The resulting electrical signals are then transformed into sonograms which will make up the 
tomographic images, after a series of processing steps. PET possesses a high level of 
sensitivity, thus allowing for the detection of low concentrations of radiotracers. For the 
purpose of imaging relevant biological operations, a targeted imaging agent is attached to the 
radioactive isotope being utilized.  Such agents include small molecules, peptides, engineered 
proteins, nanoparticles and aptamers (James and Gambhir, 2012). These agents localize the 
isotopes to regions within the specimen dependent of the presence and degree of interaction 
of the target and therefore provide information about the spatial orientation as well as the 
concentration of the target. 
   
3.1.5 PET/MRI 
 
The combination of PET and MRI imaging devices into a single simultaneous system was 
first proposed in the early 1990’s (Hammer, Christensen et al., 1994). Following this, PET 
detectors that were able to operate in strong magnetic fields were generated (Shao, Cherry et 
al., 1996). Shortly afterwards, prototype devices capable of simultaneously imaging small 
animals with PET and MRI were developed (Christensen, Hammer et al., 1995, Shao, Cherry 
et al., 1997). However, it took several years of technological developments and optimization 
before these machines became commercially available (Delso, Furst et al., 2011). The result 
is a system in which MRI provides excellent soft tissue contrast and images of anatomy, 
alongside PETs ability to target specific biochemical features within this tissue. This makes 
this an ideal tool for imaging soft tissue areas where MRI is already the preferred modality 
over CT, (e.g. brain, breast and abdomen) in which researcher hope to address specific 
molecular interactions. Importantly this allows for the assessment of these molecular features 
in a live animal model, allowing for assessment over time, as well as making the information 
obtained clinically relevant and more easily translatable to a human context. 
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3.1.6 PET Imaging of Neuroinflammation 
 
Along with perivascular cells, microglial cells represent the primary immune defence system 
in the central nervous system, when the blood-brain barrier is fully intact. These mesoderm 
derived cells are normally quiescent, however may become activated in response to neuronal 
damage or upon coming in contact with multiple activating factors.  Upon activation these 
cells change morphology from a dendritic to an amoeboid shape and produce a variety of 
further pro-inflammatory signals (Kreutzberg, 1996).  
 
The association of neuroinflammation with multiple neurological disorders including 
Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) (Halle, Hornung et al., 2008, 
Zhao, Beers et al., 2010, Heneka, Kummer et al., 2013) has led to the development of several 
new specific radiotracers. Many of these tracers target the peripheral benzodiazepine receptor 
(PBR)/18kDa translocator protein (TSPO). The PBR/TSPO receptor is a protein found on the 
mitochondrial membrane and is generally expressed in peripheral organs including heart, 
endocrine glands, adrenal glands, and lungs. However, PBR/TSPO is also expressed at low 
levels in microglial cells residing in the brain. This expression has been shown to 
dramatically increase in response to microglial cell activation in events of brain injury and 
neuroinflammation (Hardwick et al., 1999).  
 
 
[11C]PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline 
carboxamide) was the first ligand used for radiolabelling to determine PBR/TSPO expression 
levels, as a biomarker for inflammation (Benavides, 1988). While in vitro studies have shown 
relatively high levels of expression of PRB/TSPO in astrocytes (Itzhak et al, 1993), in vivo 
studies performed with [11C]PK11195, in patients with hippocampal sclerosis marked by 
astrogliosis showed no increase in [11C]PK11195 binding, indicating signals observed are 
generated predominately or exclusively by microglial activation (Banati et al., 1999). 
Autoradiography and histological data from autoimmune encephalomyelitis tissue has also 
shown increased binding of [3H]PK11195 on activated microglia, but not on reactive 
astrocytes (Shah et al., 1994). As such, in vivo usage of this compound has been shown to be 
highly selective for activated microglia and has been utilized in clinical trials (Dodel, Spottke 
et al., 2010, Chaudhry, Hallak et al., 2012), as well as in identifying a role for microglial 
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activation and neuroinflammation in the progression of Alzheimer’s disease (Bartels and 
Leenders, 2007).  
 
 
 
 
Figure 3.4 Chemical structure of [11C]PK11195 and [18F]PBR111 (Van Camp et al., 
2010). Both PK1195 and PBR111 have a high affinity for binding to the PBR/TSPO receptor 
both in vitro and in vivo. 
 
 
More recently another tracer, [18F]PBR111 (2-(6-chloro-2-4-(3-
fluoropropoxy)phenyl)imidazo[1.2-α]pyridine-3-yl)-N,N-diethylacetamide) (Figure 3.4) has 
been labelled with 18F  and shown to be metabolically stable, while having a high affinity for 
binding to the PBR/TSPO receptor both in vitro and in vivo. Further, this tracer has shown a 
high level of specifity for the PBR/TSPO receptor over the central benzodiazepine receptors 
and to have nearly identical binding specificity as that observed with [11C]PK11195, through 
competive binding experiments in vivo and in vitro (Van Camp, Boisgard et al., 2010). Given 
the longer half-life of 18F (T1/2 = 109.8 min) over 
11C (T1/2 = 20.4 min), this tracer is also more 
readily useful in many situations, particularly when long acquisition periods are preferable or 
when PET imaging will occur at sources not located close to a cyclotron.   
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The aim of this work was to better understand the phenotypic abnormalities observed in a 
knockout (KO) rat model of A-T utilizing structural MRI as well as the neuroinflammation 
tracer PBR111 analyzed with PET-MRI, autoradiography and a gamma counter. This 
imaging allowed for three dimensional reconstruction of both the region of the spinal cord 
relevant to the paralysis observed in these animals, as well as cerebellum, facilitating 
volumetric analysis as well as quantification of gray/white matter ratios. Further, utilization 
of the (18F)PBR111 tracer allowed for the quantification of  microglial activation in 3 
dimensions in a living animal. 
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3.2 Materials and Methods 
 
3.2.1 Ataxia Behavioral Scoring 
 
3 wild-type and knock-out rats were scored blindly for the presence of unusual gait, kyphosis, 
and their ability to walk across a narrow ledge as described in (Guyenet, Furrer et al., 2010). 
Hind limb motility (movement of the rats hind limbs when lifted by its tail) was substituted 
for the hind limb clasping test from this publication, as no such clasping was observed in our 
animal model. Analysis was performed 3 times per week, with at least one day of rest 
between analyses. Animal were analysed single blinded and genotype of individual animals 
was revealed at the end of total analysis. 
 
3.2.2 MRI Acquisition 
 
Rats were anaesthetised with isoflurane (IsoFlo, Abbott Laboratories) at a dose of 3% in a 
closed anaesthetic induction chamber. MRI scans were performed on a Bruker (Ettlingen, 
Germany) 7 T ClinScan spectrometer running Siemens Numaris/4 MR B17. The rats were 
imaged in an 86-mm id volume 1H coil. A 3D gradient echo sequence, fl3d_dixon, was used 
with the following parameters: repetition time 12 ms, echo time 1.07 ms, pulse angle 4 and 
21°, field of view 105 x 39 x 28 mm, acquisition matrix 416 x 156 x 112, slice partial fourier 
6/8, number of averages 6, and total acquisition time 33 min. Selected figures are shown from 
the images acquired with the pulse angle 21°. 
 
3.2.3 Pathology 
 
After imaging, all animals were perfused with 4% paraformaldehyde (PFA) following a rinse 
with 1 X PBS. Spine and brain samples were then stored at 4°C in 4% PFA until sectioning. 
Fixed tissues were sectioned by QIMR Berghofer histology facility and serial tissue sections 
were made at a 4uM thickness. Before staining paraffin was removed from slides and they 
were rehydrated using a Leica Autostainer XL. Slides were stained for haematoxylin and 
eosin (H&E) using the Leica Autostainer XL and images were captured using the Aperio XL 
(Leica Biosytems, USA) and then analysed with Imagescope software (Leica Biosytems, 
USA) or directly from the slides by a certified veterinary pathologist.   
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3.2.4 PET/MRI Acquisition 
 
Rats were anaesthetised with isoflurane (IsoFlo, Abbott Laboratories) at a dose of 3% in a 
closed anaesthetic induction chamber. Anaesthetised rats, with a cannulated tail vein, were 
placed in a Bruker 7T ClinScan with 300mm bore magnet, with a 40 mm ID rat head RF coil, 
using Siemens Singo VB17 MRI platform and a removable PET insert, consisting of 3 rings 
of 16 detector blocks with 15x15 LSO crystals per block, operating with Siemens 
IAW(Bruker, Germany). Siemens IRW was used to register and analyse PET and MR data 
collected (Siemens). Physiological monitoring (respiratory using a sensor probe) was 
achieved throughout all experiments using an animal monitoring system. The rat was injected 
with 15-20 MBq of [18F]PBR111 solution in a volume of approximately 400µL via the tail 
vein.  Dynamic PET data acquisition was performed for 60 min. The list-mode data were 
sorted into 60 dynamic frames of 30sec and reconstructed with an ordered-subset expectation 
maximization (OSEM2D) algorithm and analysed using the IRW software (Siemens). MRI 
images were acquired simultaneously with the PET acquisition, including anatomical 3D, T1 
weighted gradient echo VIBE sequence and 2D T2 weighted spin echo images. PET and MRI 
datasets were aligned using IRW software (Siemens) to ensure good overlap of the organs of 
interest. Three dimensional ROIs were placed within the brain and over the carotid 
artery.  Activity concentrations were then expressed as percent of the decay-corrected 
injected activity per cm3 of tissue that can be approximate as percentage injected dose/g 
(%ID/g). 
 
3.2.5 Autoradiograpy 
 
Whole brains obtained from ATM KO (n=2) and WT (n=2) rats at 5 months of age were 
sectioned into 4 uM sections. Sections were pre-incubated in 50mM Tris-HCL for 5 minutes 
at room temperature. 200 uL of solution containing 1.16x10-9 mole/mL of [18F]PBR111 
were added for each section where total binding was being measured and 200 mL of a 
solution containing 1.16x10-9 mole/mL of [18F]PBR111 and 20uM of PK11195 were added 
to each section where non-specific binding was being measured. Slides incubated at room 
temperature for 30 mins. Sections rinsed 3 times for 30 seconds in Tris/HCl to eliminate 
unbound ligand. Sections were then washed in distilled water 3 times for 1 min to remove 
excess buffer salts. Sections were dried and then analysed for presence of tracer. 
45 
 
3.2.6 Gamma Counter Analysis 
 
2 KO and WT rats were used for this analysis. Rats were anaesthetised with isoflurane 
(IsoFlo, Abbott Laboratories) at a dose of 3% in a closed anaesthetic induction chamber. The 
rat was injected with approximately 15-20 MBq of (18F)PBR111 solution in a volume of 
400µL via the tail vein. After 65 minutes, rats were euthanized and brains were sectioned into 
cerebellum, medulla pons, midbrain, hypothalamus/thalamus, hippocampus, striatum, frontal 
cortex and posterior cortex. Each region of each animal was placed in a separate tube and 
analysed using a WIZARD2 gamma counter (Perkin Elmer). Activity concentrations were 
then expressed as percent of the decay-corrected injected activity per cm3 of tissue that can be 
approximate as percentage injected dose/g (%ID/g). 
 
3.2.7 Statistics 
 
Data represent mean ± s.e.m of the number (n) of independent experiments unless indicated 
otherwise. Statistical significance has been calculated by a two-way ANOVA with Bonferroni 
post-tests to compare replicate means between the indicated groups for all experiments or via 
student’s T-test where appropriate. 
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3.3 Results 
 
 
 
Figure 3.3 Composite phenotype scoring of Atm -/- rat model. Animals were scored for 
the presence of abnormal gait, kyphosis, their ability to walk across the narrow ledge, as well 
as hind limb movement. All KO animals presented with hind limb paralysis resulting in high 
composite phenotype score which progressed rapidly, resulting in all KO animals reaching 
endpoint within 1-3 after detection of phenotype above detection threshold. 
 
As human patients diagnosed with A-T suffer from severe ataxia, with the majority of them 
being wheelchair bound by their early teens (Su and Swift, 2000), a behavioural assay 
developed for the characterization and quantification of cerebellar ataxia in rodent models 
(Guyenet, Furrer et al., 2010) was utilized to characterize the presence of ataxia in these 
animals. Assays were performed blinded and animals were scored on the presence of 
abnormal gait, kyphosis, their ability to walk across the narrow edge of a cage, as well as 
hind limb movement. In all three of the sick animals observed the progression from 
observable disease (considered a collective score of 5 or above) to an end point, at which 
point the animals had to be euthanized, occurred over a 1-3 week time span (Figure 3.3). At 
this point the animals had bilateral hind limb paralysis. Incontinence and loss of tail motility 
were also observed at endpoint in these animals, consistent with a prognosis of damage in the 
lower regions of the spinal cord.    
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Figure 3.4 3D Reconstruction and volumetric measurement of KO and WT cerebellum 
in pre-disease 5 month old rats. (A) Representative coronal, sagittal, and axial sections 
from manual segmentation. (B) Representative 3-D reconstruction of cerebellum. (C) 
Cerebellar volumes were not significantly different between Atm +/+ and Atm -/- animals 
and correction for individual animal body weight (D) or total brain volume (E) did not 
produce a significant difference between groups. 
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Given the consistent presence of cerebellar atrophy in MRI studies of human A-T patients  
(Farina, Uggetti et al., 1994, Sardanelli, Parodi et al., 1995, Tavani, Zimmerman et al., 2003, 
Wallis, Griffiths et al., 2007) and its association with locomotors dysfunction in this disease, 
whole brand structural MRI was performed. Rats at 5 months of age were used as no signs of 
paralysis or lymphomagenesis has been observed in the Atm KO rats at this age (Quek et al., 
Unpublished), yet the rats had grown to a stable healthy weight.  
 
 
Figure 3.5 Gray/white matter ratios in KO and WT cerebellum in pre-disease 4 month 
old rats. (A) Representative sections of cerebellum assessed for gray/white matter ratios. (B) 
No significant difference in the ratio of gray to white matter in the cerebellum was observed 
between the Atm +/+ and Atm -/- groups. 
 
3D reconstructions of the cerebellum were produced by manual segmentation of 2D sections 
(Figure 3.4 A) that were then reconstructed using ITK-SNAP software (Figure 3.4 B). 
Segmentations were performed prior to decoding rat genotype identity and cerebellar 
volumes were found to be consistent amongst rats of both genotypes with the average volume 
of an Atm +/+ rat cerebellum being 241.8mm3 (SD= 10.9mm3) and the average volume of an 
Atm -/- rat being 223.0mm3 (SD=12.3mm3). As our Atm -/- rat model has been shown to be 
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smaller than its Atm +/+ counterpart, cererbellar volumes were corrected as a ratio of 
individual rat weight (Figure 3.4 D) as well as individual whole brain volume (Figure 3.4 E). 
However, neither corrections resulted in significant difference between Atm +/+ and Atm -/- 
groups.    
Reduced gray matter volume has been observed in both cerebellar hemispheres of human A-
T patients relative to age matched controls (Sahama, Sinclair et al., 2014) and gray/white 
matter ratios have been shown to change with degeneration in normal aging (Salat, Lee et al., 
2009). As such, the ratio of gray to white matter was assessed in the 3D reconstructed 
structural images, however no significant difference was observed between Atm -/- and Atm 
+/+ groups (figure 3.5). 
 
 
 
Figure 3.6 Atlas of rat spine. Regions residing within vertebrae T12-L3 best correlate with 
the loss of motor function in hind limbs, loss of tail motility and incontinence observed in the 
Atm -/- rat model (from (Sengul, 2013)). 
 
Given the presence of spinal atrophy observed in some human A-T patients via MRI 
(Kieslich, Hoche et al., 2010), as well as the paralysis phenotype observed in this rat model, 
structural MRI imaging was performed on a section of the spine in these animals. In an 
attempt to optimize resolution and contrast, a smaller receiving coil had to be utilized, 
limiting the section of the spine which could be visualized. Given that the phenotype 
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presented loss of motility in the hind legs, incontinence, and loss of tail motility, the section 
of the spine containing nerve bundles pertaining to these functions were identified using a rat 
spinal cord atlas (Sengul, 2013). Thoracic regions 12 and 13 (T12-T13), as well as lumbar 
regions 1-3 (L1-L3), best correlated with the function of the muscle groups pertaining to hind 
limb motility (Figure 3.5) and were thus chosen for analysis.  
 
 
Figure 3.7 Structural MRI of KO and WT spines in pre-disease 5 month old rats. 
Aligned spines showed no observable gross phenotypic differences between KO and WT rats 
at 5 months of age. 
 
At 5 months of age all animals observed showed no signs of hind limb weakness or paralysis. 
Structural images of the T12-L3 region of the spine were aligned and assessed for the 
presence of any gross phenotypic irregularities, however no such irregularities were observed 
(figure 3.7).  
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Figure 3.8 3D Reconstruction and volumetric measurement of KO and WT spines in 
pre-disease 5 month old rats. (A) Representative 3D rendering of spinal vertebrae T12-L3 
in an Atm -/- rat.  (B) No significant difference in spinal cord volume was observed within 
any of the vertebrae measured between KO and WT rats. 
 
Following alignment and initial analysis for gross morphological differences, 3D images of 
the slices were reconstructed, allowing for volumetric quantification of the individual 
vertebrae regions, in each of the animals (Figure 3.8 A). As intervertebral discs and location 
of the ribs in axial sections were used to best identify location within the spine, volumetric 
measurement represents the volume within the vertebrae and not the spinal segments of the 
same name (Figure 3.6). No significant differences in volume were observed in spinal cord 
segments contained within any of the vertebrae analysed (Figure 3.8B) 
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Figure 3.9 3D Gray/white matter ratios in KO and WT spines in pre-disease 4 month 
old rats. 
 
 
While no data currently exists on the relative degeneration of gray and white matter tracks in 
the spinal cord of A-T patients, distinct patterns of gray and white matter degeneration have 
been observed from MRI imaging of spinal neurodegeneration in multiple sclerosis (MS) 
(Inglese, Oesingmann et al., 2011),. 
 
 Gray to white matter ratios were obtained from analysis of the 2D slices (Figure 3.9 A) 
composing the 3D reconstructed spinal segments (Figure 3.9B) in hopes of identifying a 
novel A-T characteristic that may help explain the observed paralysis phenotype. However, 
no difference in the ratio of gray and white matter tracts in the spine were observed in any of 
the regions analysed, between KO and WT animals (Figure 3.9 C).  
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Figure 3.10 3D Reconstruction and volumetric measurement of KO and WT cerebellum 
in rats at onset of hind limb paralysis. (A) Cerebellar volumes were not significantly 
different between Atm +/+ and Atm -/- animals and correction for individual animal body 
weight (B) or total brain volume (C) did not produce a significant difference between groups. 
 
As no difference in cerebellar volume (Figure 3.4) or gray/white matter ratios (Figure 3.5) 
were observed between  adult (5 month old) Atm -/- and Atm +/+ rats, at an age prior to the 
onset of paralysis in this model, these metrics were assessed in paralysed Atm -/- rats and 
compared with age matched Atm +/+ controls. Again, no differences were observed in total 
cerebellar volume (Figure 3.10 A) or cerebellar volume relative to the weight of the rat 
(Figure 3.10 B) and relative to the total brain volume (Figure 3.10 C). Further, no difference 
in gray to white matter ratios where observed in the cerebellum of paralysed rats (Figure 3.10 
D). 
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Figure 3.11 Structural MRI of KO and WT spines in rats with hind limb paralysis. 
Structural MRI of the T12-L3 region of the spinal cord shows distinct lesions (*) in the spinal 
columns of all paralysed Atm -/- rats analysed.  
 
Structural MRI imaging was performed on the spinal column of three Atm -/- and three age 
matched Atm +/+ rat spines. Structural images of the T12-L3 region of the spines were 
aligned with their age matched controls and assessed for the presence of any gross phenotypic 
irregularities. In all three of the paralysed Atm -/- rats large lesions were observed within the 
spinal column and the spinal cords appeared distorted. Further some differences were 
observed in the morphology of the vertebra, with the transverse processes showing irregular 
morphology at the region surround the lesions.  (Figure 3.11).  
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Figure 3.12 H&E staining of sagittal sections of Atm -/- spine at regions of detected 
lesions.  Pathological analysis of sagittal H&E sections reveals presence of lymphomas at the 
site of lesions detected via structural MRI. 
 
While structural MRI was able to detect the presence of lesions in the T12-L3 region of the 
spinal column, the composition of the lesions could not be identified at this resolution.  
Hematoxylin and eosin staining was performed on cross section of the spinal cords, at the site 
of the lesions observed in the structural MRI images. In all three of the Atm -/- paralyzed rats 
analyzed, the presence of lymphomas were identified by a veterinary pathologist at the site of 
the lesions, within the spinal column. Further, lymphoma was observed within the vertebral 
bodies, as well as transverse processes of the vertebrae in these animals.   
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Figure 3.13 Structural MRI of non paralyzed rats at end point. Rats that had to be 
euthanized due to reaching an endpoint other than paralysis do not have detectable lesions in 
the T12-L3 spinal regions.  
 
The presence of large lymphomas within the T12-L3 vertebral columns of all paralyzed rats 
indicates a potential role for these lymphomas in the paralysis phenotype observed in these 
mice. To assist in the elucidation of their potential role in this paralysis phenotype three 
animals that were at endpoint (showing signs of severe fatigue and kyphosis likely associated 
with the large burden of lymphoma found in the Atm -/- rats (Quek, Luff et al., 2015)), but 
that showed no signs of paralysis were imaged. No structural abnormalities or lesions were 
observed within this non paralyzed group that were detectable by MRI (Figure 3.13).  
 
While no structural lesions were detectable by structural MRI analysis, several sections were 
taken from each of the vertebrae comprising the T12-L3 region and were sent for 
pathological examination, where pockets of lymphomas were found to be present in 2/3 of 
the non-paralysed rats (Figure 3.14). These lymphomas were predominantly present in the 
vertebral bodies and transverse processes of the vertebrae, however a small amount of 
lymphoma was found in the spinal column of one of the two non-paralysed rats.   
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3.14 H&E staining of non-paralyzed rats. While no lesions were visible in the non-
paralyzed rats, pathological examination revealed the presence of lymphomas in the T12-L3 
region predominantly in within the bone marrow. 
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Figure 3.15 Autoradiography of PBR-111 binding in 5 month old rats. (A) Pre-
incubation with PK11195 reveals low levels of non-specific binding of PBR-111in rat brains 
with pronounced increases observable in Atm +/+ (B) and Atm -/- (C) rats. 
 
 
A recent publication from our research group has shown an increased frequency of microglial 
activity in Atm -/- rats, relative to Atm +/+. Given the association of neuroinflammation with 
multiple other neurological disorders including Alzheimer’s disease and amyotrophic lateral 
sclerosis (ALS) (Halle, Hornung et al., 2008, Zhao, Beers et al., 2010, Heneka, Kummer et 
al., 2013), a role for excessive activation of microglia, resulting in neuronal cell death or 
possibly increased pruning of neuronal axons, has been proposed in A-T (Quek, Luff et al., 
2015). As such, the PBR-111 tracer, which binds to the TSPO receptor was chosen for 
PET/MRI studies, as it has been shown to be specific to activated microglia within the rat 
brain (Van Camp, Boisgard et al., 2010). 
 
To test the specificity of the tracer within our rat model we first performed autoradiography 
on brain slices from the rats.  Ctrl samples were pre incubated with the TSPO binding ligand 
PK11195 prior to incubation with 18F-PBR111 and showed low levels of 18F not specific to 
any regions of the brain (Figure 3.15 A). However, in the absence of the coemptive PK11195 
ligand 18F-PBR111 was detected throughout the brain in both Atm +/+ (figure 3.15 B) and 
Atm -/-  (figure 3.15 C) axial cross sections.  
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Figure 3.16 Gamma counter analysis of several brain regions of PBR-111 injected rats. 
No significant difference in measurable levels of PBR-111 where detected in any of the 
observed brain regions 65 minutes following intravenous tail vein injection, with the 
exception of a decrease in activity in the striatum (P> 0,05).  
 
To assess the relative binding of the 18F-PBR111 between Atm +/+ and Atm -/- rats in 
multiple regions of the brain, rats were injected with the radioactive tracer, via tail vein 
injection, and then sacrificed 65 minutes following injection. Individual regions of the brain 
were analysed using a gamma counter for total gamma emissions and then corrected to give a 
percent of the injected dose per gram of the rats total weight (Figure 3.16). No differences 
between Atm +/+ and Atm -/- rats were observed in any of the regions tested with the 
exception of a decrease in activity in the striatum (P> 0,05). 
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Figure 3.17 Kinetic PET/MRI analysis of PBR-111. (A) PET/MRI overlay of regions of 
interest (ROI) for analysis of cerebellum (blue) and mid-brain (green). Kinetic analysis of 
18F-PRB111 shows a more rapid initial uptake of the tracer in Atm +/+ rats relative to Atm -
/- in both the cerebellum (B) and mid-brain (C) with uptake normalizing at approximately 40 
mins in both groups.  
 
To assess the kinetics of 18F-PBR111 in the rat brain following injection, while being able to 
identify distinct regions of the brain, small animal PET/MRI imaging was employed (Figure 
3.17 A). In both the cerebellum (Figure 3.17 B) and the mid-brain (Figure 3.17 C) regions 
18F-PBR111 uptake appears more rapid in Atm +/+ rats than the Atm -/- rats, however no 
significant difference was measured. By 40 minutes binding to the receptor for in Atm -/- rats 
had caught up with that observed in Atm +/+ rats.  
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Figure 3.18 Static PET/MRI analysis of PBR-111. (A) PET/MRI overlay of regions of 
interest (ROI) for static 60 min analysis of cerebellum (blue) and mid-brain (green). Static 
analysis of 18F-PRB111 showed no significant difference in in Atm +/+ rats relative to Atm -
/- in both the cerebellum (B) and mid-brain (C) regions.  
 
To obtain a more thorough reading of final uptake, static PET/MRI imaging was performed at 
60 minutes post injection of 18F-PBR111 (Figure 3.18 A). Neither the cerebellum (figure 3.18 
B), nor the mid brain (Figure 3.18 C) showed a significant difference in levels of 18F-PBR111 
at this static time point. 
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3.4 Discussion 
 
 
Prior to this rat model the prominent animal model of A-T has been the mouse, however the 
mouse does not show the severe neurological symptoms, associated with this disease (Lavin, 
2013). This rat is the first rodent model to show a neurological defect as approximately 50% 
of the animals develop bilateral hind limb paralysis (Quek, Luff et al., 2015). The progression 
of this phenotype is quite rapid (Figure 3.3) once abnormalities become apparent, indicative 
of a rapidly progressing underlying etiology. 
 
The most prominent feature detected in MRI studies of human A-T patients is the presence of 
cerebellar atrophy (Farina, Uggetti et al., 1994, Sardanelli, Parodi et al., 1995, Tavani, 
Zimmerman et al., 2003, Wallis, Griffiths et al., 2007), however no such atrophy was 
detectable in either adult Atm -/- 5 month old rats showing no signs of paralysis (Figure 3.4) 
or adult Atm -/- rats presenting with paralysis (Figure 3.10). This is consistent with the 
histological  observations made in this model, which noted no difference in the number or 
distribution of purkinje cells, or the thickness of the molecular layer of the cerebellum (Quek, 
Luff et al., 2015) This may be a result of inter-species differences or could possibly be due to 
the relatively short life-span of these animals, as a result of a greater than 90% incidence of 
lymphoma. 
 
Given that paralysis in these animals is restricted to the hind limbs it is probable that 
alterations to the spinal cord residing between thoracic vertebrae 12 and lumbar vertebrae 3 
are responsible for the paralysis. As such, structural MRI imaging was performed in these 
regions. No aberrations were detected in any of the non-paralysed rats (Figure 3.7-3.9), 
however large lesions were detected in all three of the paralysed rats analysed (Figure 3.11). 
Pathological analysis identified the lesions as lymphomas. The presence of lymphomas is the 
spinal column can result in metastatic spinal cord compression, a condition that typically 
results in paralysis, if not rapidly treated (Cole and Patchell, 2008). The presence of 
lymphomas in the spinal column has been associated with paralysis in mouse models of 
lymphoma (Ghetie, Richardson et al., 1990, Ghetie, Tucker et al., 1992, Ochakovskaya, 
Osorio et al., 2001, DiJoseph, Goad et al., 2004) , as well as in cats in a veterinary medicine 
setting (Spodnick, Berg et al., 1992). While, pockets of lymphoma were identified in 2 sick, 
but non-paralysed rats (Figure 3.14) no lesion was detected in the spinal column by MRI 
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(Figure 3.13) and there was no evidence of spinal cord compression from this imaging. As 
such, it is possible that these rats would have developed paralysis later in life, if lymphomas 
in other regions of the body had progressed more slowly, or if ethical considerations were not 
required and the rats did not need to be euthanized.  
 
Given the proposed role for increased microglial activity in neurodegenerative diseases such 
as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) (Halle, Hornung et al., 2008, 
Zhao, Beers et al., 2010, Heneka, Kummer et al., 2013), as well as observed increase in the 
frequency of microglial activation in this model (Quek, Luff et al., 2015) radiological studies 
were performed on this animal model utilizing the TSPO specific tracer 18F-PBR111. 
Analyses performed utilizing simultaneous PET/MRI showed an increase (though non-
significant) in the initial uptake of this tracer in Atm +/+ relative to Atm -/- rats (Figure 3.17), 
indicating that there may be some differences in binding affinity to the TSPO receptor 
between these animals. However, static studies, at a time beyond saturation, as well as studies 
performed using a gamma counter on several regions of the brain, found no significant 
differences in 18F-PBR11 activity. It is possible that while there was an increase in the 
frequency of activated microglia in 2D slices, this difference does not translate to an increase 
in the total number of activated microglia within the brain, or possibly that the level of 
activation was below the limit of detection for the PET/MRI and gamma counter studies. 
Another consideration is that there may be a difference in the degree of expression of the 
TSPO receptor on activated microglia cells, between the Atm -/- and Atm +/+ animals. While 
no difference in TSPO gene expression levels was observed between neural cultures derived 
from iPS cells of A-T patients, relative to controls on the publicly available Stemformatics 
database (Wells, Mosbergen et al., 2013), these differences may be unique to the rat model.   
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4.0 Bone Marrow Transplantation in a Rat Model of 
Ataxia Telangiectasia 
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4.1 Introduction  
 
Hematopoietic stem cells (HSCs) were first successfully used to treat leukemias in the late 
1950s, in the form of whole bone marrow transplantation (BMT) (Thomas, Lochte et al., 
1957). This attempt was premised on earlier work which had shown that BMT was able to 
rescue rats and guinea pigs that had received otherwise lethal doses of radiation (Jacobson, 
Simmons et al., 1951, Lorenz, Congdon et al., 1952). HSC transplantation has seen many 
advances since then, and currently constitutes the majority of clinical stem cell therapies 
being used today. These therapies utilize HSCs (isolated or in combination with other cells) 
from bone marrow and umbilical cords for transplantation (Daley, 2012).  
 
More recently, techniques have been proposed resulting from the capacity to generate 
hematopoietic progenitor cell populations from pluripotent stem cells, transplantation of cells 
derived from the bone marrow and umbilical cord remain the only clinically relevant options 
for treatment of hematopoietic malignancies (reviewed in Daley, 2003). Unlike their bone 
marrow and umbilical cord derived counterparts, pluripotent derived haematopoietic 
progenitor cells do not show robust long term engraftment upon transplantation into immune 
compromised mouse models, indicating that they may not yet be ideal candidates for 
transplantation. It is difficult to elucidate the role that these xenogeneic recipients may have 
on engraftment, however, it is interesting to note that hESC derived hematopoietic cell 
engraftment has been observed using sheep recipients. A more recent study has shown that 
human pluripotent cells differentiated in vivo (in the form of teratomas in immune 
compromised mice) are also capable of engrafting immune compromised mouse recipients 
(Amabile, Welner et al., 2013), indicating that difficulties associated with engraftment may 
result from current in vitro differentiation procedures and producing a robustly engraftable 
population may be possible in the future.  
 
The barriers currently associated with using pluripotent derived hematopoietic cells, make 
bone marrow/umbilical cord transplantation the most plausible treatment for the 
hematopoietic phenotypes observed in A-T. However, given the potential risks associated 
with such a procedure BMTs have only been performed in very few A-T patients. The first 
reported BMT was performed on an A-T patient presenting with a Hyper IgM phenotype 
disorder, however not yet showing any clinical symptoms of A-T  (Ghosh, Schuster et al., 
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2012). BMT was successful in this patient with full lympho-hematopoietic reconstitution. 
However 8 months following transplantation the patient died due to encephalopathy 
and hepatic failure, at the age of 32 months. Post mortem high-throughput sequencing 
later revealed a mutation in the A-T gene of this patient. Such difficulties, associated with 
the delivery of blood products into immune compromised A-T individuals, is not 
unprecedented as an A-T patient presenting with  a high-grade B-cell non-Hodgkin's 
lymphoma suffered severe graft versus host disease after receiving platelets and red blood 
cells, which had not been irradiated, and did not survive (Watson, McLaren et al., 1997).  
More recently a 3 year old A-T patient with T-cell acute lymphoblastic leukaemia (T-ALL), 
received an allogenic matched sibling transplantation which resulted in long term survival 
(Ussowicz, Musial et al., 2013).     
 
While little clinical data exists on BMT in humans, there have now been two studies 
published using mouse models of A-T. The first such study (Bagley, Cortes et al., 2004)  that 
transplantation of bone marrow from Atm +/+ to replace the bone marrow compartment of 
Atm -/- mice, was able to restore immune function and prevent lymphomas in these mice. A 
further study utilizing GFP+ donor animals went on to show that donor bone marrow derived 
cells migrated to the  bone marrow, blood, thymus, spleen and lung tissue of recipients, 
however were not found in the cerebellum or cerebrum (Amabile, Welner et al., 2013). 
 
While the above studies show an impressive potential for BMT in the treatment of 
haematological features typical in A-T, they are lacking any potential effect such 
transplantation might have on neurological phenotypes, as these models lack the most 
prominent neurodegenerative phenotypes associated with  ataxia in humans, (Lavin, 2013).  
Our research group has produced a gene knock-out model in the rat, utilizing Zinc Finger 
Nuclease technology. This rodent model is the first to show neurological defects including 
dilated blood vessels in the eyes, microgliosis and the development of hind limb paralysis in 
approximately 50% of rats. Further, these animals share a predisposition towards 
haematological malignancy with human A-T patients and mouse models of A-T, as 
lymphomas have been detected by histological examination in greater than 90% of these 
animals (Quek, Luff et al., 2015). 
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4.2 Materials and Methods 
 
4.2.1 Maitenance of Atm -/- and Atm +/+ Rats 
 
Ethics approval for all experiments was obtained from the animal ethics committee at either 
University of Queensland and/or QIMR Berghofer Medical Research Institute, and were 
conducted within the ‘Animal Care and Protection Act QLD (2001)’, as well as the 
‘Australian Code for  the care of and Use of Animal for Scientific Purposes (2013)’. All rats 
were maintained on a 12hr light then 12 hour dark cycle at the QIMR Berghofer Medical 
Research Institute. Both food and water were constantly available throughout all experiments. 
Rats were monitored at least three times per week and monitoring increased to daily once 
presence of disease onset was observed. All paralysed rats were sacrificed, as well as any rats 
that showed serious signs of distress or fatigue. 
 
4.2.2 Genotyping of Atm -/- Rats 
 
Standard PCR was performed on DNA extracted from ear clippings with the following 
primers: forward primer 5’-ATTTCAATCTGTGTTGGCTTC-3’ and reverse primer 5’-
GCTGTTCTGATAATCCCAGAAGATA-3’. An 8 nucleotide difference in product length 
between Atm -/- (75bp) and Atm +/+ (83bp) was observable on a 4% agarose gel. 
 
4.2.3 Irradiation of Rats 
 
All bone marrow transplant recipient rats were irradiated 24 hours prior to transplantation. 
Rats were irradiated with a GammaCell 40 Exactor (Best Theratonics Ltd., CA) Caesium 137 
source, at a dose rate of 0.96 Gy/min to a total whole body dose of 4Gy.  
 
4.2.4 Intravenous Transplantation of Whole Bone Marrow Cells 
 
Bone marrow cells were sterilely harvested on the day of transplantation and kept on ice. 10 x 
106 cells were diluted in 1X PBS and injected intravenously through the tail vein into each 
conditioned recipient rat.  
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4.2.5 Detection of Engraftment 
 
Level of chimerism in the peripheral blood population was determined using real-time PCR 
as per (Xue, Chen et al., 2011). Blood samples were collected in a heparinised tube. Genomic 
DNA was isolated using a QIamp DNA blood Mini Kit (Qiagen). Primers for the male 
specific SRY gene were designed to amplify all six SRY genes (SRY1, SRY2, SRY3, 
SRY3B, SRY3C, and SRY3bl) and were designed as follows: forward primer 5’-
CGAAGGGTTAAAGTGCCACAG-3’, reverse primer 5’-
GTTCTTGGAGGACTGGTGTGC -3’. The total amount of rat genomic DNA, relative to the 
SRY DNA was calculated using the following primers for 5HTT: forward primer 5’-
TCCGCATGAATGCTGTGTAAC-3’, reverse primer 5’-TTGGCTTAGAGGGGAGGAGTC 
-3’. Each real time PCR reaction included 1X Quantitect SYBR Gree PCR Master Mix 
(Qiagen), 0.3uM of each primer, and 2 uL of sample DNA. The PCR program was 95°C for 
15 minutes, 40 cycles of 94°C for 15 seconds, 57°C for 30 seconds, and 72°C for 30 seconds. 
 
4.2.6 Flow Cytometry 
 
For peripheral blood analysis, samples were retrieved via tail vein puncture and 10 uL of 
blood was diluted in 1 mL of FCAB buffer (PBS with 2 mM EDTA and 0.5% heat 
inactivated FBS stock solutions (Sigma–Aldrich). 50 uL of diluted blood was then pippeted 
into wells of a 96-well V-bottomed plate (Sarstedt). After the supernatant was aspirated, cells 
were resuspended in a 20 uL mix of antibodies to surface antigens, as listed below, and 
incubated at 4°C for 20 minutes. After incubation 150 uL of FCAB buffer was added to each 
well and the plate was then centrifuged at 600g for 4min. After supernatant was aspirated 
cells were resuspended in 100ul of FCAB fixation and lysis buffer (PBS with 4% w/v 
paraformaldehyde and 0.0067% w/v saponin (Sigma–Aldrich), and incubated at 37°C for 10 
min. The plate was then centrifuged at 600g for 4min.  120uL of FCAB buffer was then 
added to each well and plate was centrifuged as above. Samples were then resuspended in 
100 uL and run using the high throughput screening attachment on the BD LSR 5 Laser 
Fortessa SORP flow cytometer.  
 
For all solid tissue flow cytometry tissues were macerated with a mortar and pestle and 
filtered through a 35 mm cell strainer cap (BD Falcon and diluted in FCAB buffer. Cells were 
then centrifuged at 400g for 10min. This was repeated twice.  Cells were then counted and 
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diluted to 4.0 X 106 cells/mL and 250 uL was added to each well of a 96-well V-bottomed 
plate (Sarstedt). After the supernatant was aspirated, cells were resuspended in a 100 uL mix 
of antibodies to surface antigens, as listed below, and incubated at 4°C for 20 minutes. Cells 
were then washed two times in FCAB buffer and run on a BD LSR 5 Laser Fortessa SORP 
flow cytometer.  
 
The following conjugated antibodies were used in all experiments, and all were conjugated 
antibodies from BD Bioscience: Anti-rat CD3-PE (1:500), CD4-PE/Cy5 (1:400), CD8b-FITC 
(1:400), CD45RA-APC/Cy7 (1;400), and CD90.1-FITC (1:400). Isotype controls were used 
and at least three Atm -/- and Atm +/+ rats were used for each experiment. 
 
4.2.7 Pathology 
 
After imaging, all animals were perfused with 4% paraformaldehyde (PFA) following a rinse 
with 1 X PBS. Spine and brain samples were then stored at 4°C in 4% PFA until sectioning. 
Fixed tissues were sectioned by QIMR Berghofer histology facility and serial tissue sections 
were made at a 4um thickness. Before staining paraffin was removed from slides and they 
were rehydrated using a Leica Autostainer XL. Slides were stained for haematoxylin and 
eosin (H&E) using the Leica Autostainer XL and images were captured using the Aperio XL 
(Leica Biosytems, USA) and then analysed with Imagescope software (Leica Biosytems, 
USA) or directly from the slides by a certified veterinary pathologist.   
 
Statistics 
Data represent mean ± s.e.m of the number (n) of independent experiments unless indicated 
otherwise. Statistical significance has been calculated by a two-way ANOVA with Bonferroni 
post-tests to compare replicate means between the indicated groups for all experiments or via 
student’s T-test where appropriate. 
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4.3 Results 
 
A role for Atm has been shown in DNA damage surveillance (Matei, Guidos et al., 2006) as 
well as in sensing intermediates in V(D)J recombination (Perkins, Nair et al., 2002) during 
the development of T cells. Further, studies in mouse models have shown altered thymic T-
cell development in Atm -/- mice, relative to their Atm +/+ counterparts (Bagley, Cortes et 
al., 2004, Amabile, Welner et al., 2013). As such, FACS analysis (Figure 4.1 A-D) was 
performed on thymic 
 
 
 
Figure 4.1 Thymic T-cell development in Atm KO and WT rats at 6 weeks. 
Representative FACS plots of CD3 populations in Atm +/+ (A) and Atm -/- (B) rats. 
Representative plots of CD4 and CD8 staining within the CD3+ gated population in Atm +/+ 
(C) and Atm -/- (D) rats. (E) A significantly higher frequency of CD3+ cells were observed 
in Atm +/+ relative to Atm -/- rats . (F) A significantly higher frequency of CD4+/CD8+ cells 
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were observed in Atm -/- relative to Atm +/+ rats. Error bars are s.e.m. *, P < 0.05, **, P < 
0.01). 
 
derived lymphocyte populations in young (6 week) old rats. Detection of the pan T-
lymphocytic marker CD3 showed a significant (P=0.017) decrease in the frequency of CD3+ 
cells within the thymus of Atm -/- rats relative to Atm +/+ rats (Figure 4.1 E). Further 
detection of surface bound CD4 and CD8 with the CD3+ gated population revealed a 
significant (P = 0.008745) increase in the CD3+/CD4+/CD8+ T-cell progenitor population.  
However by 4 months of age no discernible differences in any of these population could be 
detected (Figure 4.2)  
 
 
 
Figure 4.2 Immunophenotype of peripheral blood in adult rats. (A) FACS analysis for 
CD3+ cells reveals no significant difference in the frequency of total T-cells within the 
peripheral blood. (B) FACS analysis of CD4 and CD8 cells within the CD3+ population 
reveals no significant difference in any of the T-cell sub-set populations, as well as a very 
low frequency of T progenitor (CD4-/CD8- and CD4+/CD8+) cells. (C) FACS analysis fo B-
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cell marker CD45RA shows a lower, though insignificant (P=0.21) frequency of B cells. (D) 
HSC/Lymphocyte progenitor marker expression is not significantly different between groups, 
as assessed by CD90.1 FACS. 
 
 
 
 
 
Figure 4.3 Schematic representation of bone marrow transplantation experiments. Bone 
marrow transplantations were performeded using male donors and female recipients. 
Transplants were perform performed using both Atm +/+ and Atm -/- donors into Atm -/- 
recipients. Recipients were assessed for engraftment, survival, T-cell phenotype, presence of 
lymphomas, and paralysis.   
 
 
Unlike many of the common mouse models for BMT, where slight variations in cellular 
surface proteins can be used to distinguish donor cells within a recipient, working with the rat 
model required an alternative approach to detecting cells derived from the donor. Therefore, 
all male donors were used and transplantations were performed with female recipients. A 
total of 15 Atm KO rats received BMT from Atm WT donors and 5 received transplants from 
Atm KO donors, via tail vein injection (Figure 4.3). Recipients were then monitored regularly 
and were measured for the level of engraftment of the donor cells, their survival, the presence 
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of paralysis and lymphomas, and immunophenotyping was performed on the peripheral 
blood, as well as the lymphoid organs when the animal became sick.  
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Figure 4.4 Engraftment of donor cells. The level of donor engraftment, as assessed 
using the ratio of the male specific gene SRY relative to total DNA as measure by 
primers for the 5HTT gene, shows engraftment levels ranging between 55 and 85%. 
Engraftment levels in most recipients decreased between 2 and 4 months.  
 
 
In order to quantify the degree of engraftment of donor cells with the recipients (the 
level of chimerism) peripheral blood samples were taken from the recipient animals 
and DNA was extracted for RT-PCR. The male specific gene sex-determining region Y 
(SRY) was used to measure the presence of male DNA and the 5HTT gene was used for 
total DNA content, as had been previously described for the detection of male/female 
chimerism within the rat (Xue, Chen et al., 2011). The level of chimerism ranged from 
approximately 55% up to 85% in recipients. Chimerism was measured in each rat at both 2 
and 4 months following transplantation (Figure 4.4). In all but two cases the level of 
chimerism was found to be lower at four months than it had been at the two month time 
point.    
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Figure 4.5 Effect of donor cell genotype (Atm -/- vs Atm +/+) on survival of transplant 
recipients. Atm KO rats which received bone marrow derived from WT donors significantly 
outlived recipients that received bone marrow from KO donors. 
 
 
A-T patients have been shown to have a very high frequency of chromosomal aberrations on 
chromosomes 7 and 14, at site of T-cell receptor genes (approximately 40X higher than the 
general population) (Aurias, Dutrillaux et al., 1980)  and it has been proposed that aberrations 
resulting from defective V(D)J recombination are the primary cause of the presence of 
leukemias within A-T patients and therefore they are a result of cellular intrinsic properties  
(Taylor, Metcalfe et al., 1996). However, given the influence that the niche can have on 
cancer progression (Cao, Ding et al., 2014) particularly in response to irradiation (Nguyen, 
Oketch-Rabah et al., 2011), an irradiated recipient that had received bone marrow from a KO 
donor was used to control for this. Bone marrow transplant recipients that received 
transplants from WT donors significantly (P = 0.0015) outlived those that received 
transplants from KO donors (Figure 4.5).   
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Figure 4.6 Increased lifespan in Atm -/- bone marrow transplant recipients. ATM KO 
rats that received bone marrow tranplants from WT donors (BMT WT>KO) lived 
significantly longer than KO rats that did not undergo bone marrow transplantation.  
 
 
While a control, which also accounts for the effect of radiation and the BMT procedure is 
appropriate, it is more directly clinically relevant to compare the BMT recipient rats to KO 
rats that did not receive a BMT, to assess whether the risks associated with this procedure 
may be worthwhile in this particular model. Atm KO rats that receive a BMT lived 
significantly longer than those that did not receive a transplant (Figure 4.6, P = 0.0056) 
within an increase in median lifespan in BMT recipients from 6.3 months to 10.1 months. All 
of the recipient animals showed signs of disease similar to those of the KO animals that did 
not receive BMT, including general fatigue, kyphosis, and loss of appetite at endpoint. 
However, only 1/15 of the BMT recipient animals developed hind limb paralysis.   
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Figure 4.7 Pathology of transplant recipients. Lymphomas were found to be present 
in at least one lymphoid tissue (thymus, spleen, or bone marrow) in all five recipients 
that underwent pathological analysis. 
 
 
To ascertain the cause of death in BMT recipients, samples were sent to a veterinary 
pathologist for assessment. Given the previous detection of lymphoid malignancy in 
these animals (Quek, Luff et al., 2015), as well as the presence of enlarged spleens  
during post mortem, lymphoid tissues (thymus, spleen, and bone marrow) were chosen 
for pathological analysis. Of the five animals that underwent analysis, all were found to 
have lymphomas present (Figure 4.7). Lymphomas were detected in at least one of the 
three tissues assessed for each animal.    
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Figure 4.8 T-Cell immunophenotype in recipient rat peripheral blood at endpoint. (A-
D) Representative plots of CD4 and CD8 staining within the CD3+ gated population of WT 
(A) pre-disease KO rats that had not received a BMT (B) and sick BMT recipient rats that 
had received bone marrow transplations (C and D), showed two distinct haematological 
phenotypes in sick animals. 
 
 
To further assess the haematopoietic malignancies present in the transplant recipients, 
immunophenotyping of CD4 and CD8 within the T-cell (CD3+) gated population was 
performed on peripheral blood samples from these animals (Figure 4.8 A-D). Two distinct 
phenotypes were observed in these animals (Figure 4.8 C and D) with ¾ of the recipients 
showing a significant (P=0.02) increase in the presence of CD4+/CD8+ T cell progenitor 
population and ¼ recipients showing a marked increase in the presence of CD4-/CD8- cells, 
an earlier T-cell progenitor population. All animals showed a significant (P = 0.032) decrease 
in the presence of the CD4+/CD8- cells in this peripheral blood population.  
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Figure 4.9 FACS Analysis of lymphoid tissues in recipients at endpoint. FACS analysis 
for CD3 showed an increase (though non-significant) in the presence of T-cells in the spleen 
(A), thymus (B) and bone marrow (C). CD4 and CD8 subsets within the CD3+ cell 
population were highly variable in the spleen (D), thymus (E) and bone marrow (F). The rat 
B cell marker CD45RA expression was significantly (P = 0.00589) lower in the spleen (G) 
however no differences were observed in the thymus (H) or bone marrow (I). Increases 
(though non-significant) were observed in CD90.1 expression in the Spleen (J), Thymus (K), 
and bone marrow (L). 
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Given the presence of lymphomas in multiple lymphoid organs observed by pathology 
(Figure 4.7), as well as the presence of increased CD4+/CD8+ or CD4-/CD8- T-cell 
progenitor populations (Figure 4.8) immunophenotyping was performed on the spleen 
thymus and bone marrow of recipient rats at endpoint, as well as age matched controls. 
Analysis for CD3 showed a consistent (though non-significant)  increase in the presence of T-
cells in the spleen, thymus and bone marrow of sick animals (Figure 4.9 A-C). CD4 and CD8 
subsets within the CD3+ cell population were highly variable in these tissues (Figure 4.9 D-
F), with no significant differences observed. The rat B cell marker CD45RA expression was 
significantly (P = 0.00589) lower in the spleen (Figure 4.9 G) of sick animals, however no 
differences were observed in the thymus or bone marrow (Figure 4.9 H-I). Increases (though 
non-significant) were observed in CD90.1 expression in the Spleen, Thymus, and bone 
marrow (Figure 4.9 J-L) of sick animals. 
 
 
 
Figure 4.10 Structural MRI of bone marrow transplant recipient spines at endpoint. 
MRI analysis on the region spanning thoracic vertebrae 12 to lumbar vertebrae 3 (T12-L3) 
revealed no observable lesions in all 3 BMT recipient animals analysed. 
 
 
 
 
80 
 
As an association was noted between the presence of lymphomas in the spinal column within 
the region spanning thoracic vertebrae 12 to lumbar vertebrae 3 (T12-L3) observed in the 
MRI studies (Figure 3.11) and paralysis in these animal, MRI analysis was performed on this 
region in three of the bone marrow transplant recipients that did not show signs of paralysis at 
endpoint. Unfortunately, we were unable to perform MRI analysis on the one transplant 
recipient that did develop paralysis as the MRI was not yet optimized at that point. Of the 
three analyzed animals, no detectable lesions were observable in this region (Figure 4.10).   
 
 
 
Figure 4.11 H&E staining of bone marrow transplant recipient spines. Pathological 
analysis of sagittal H&E sections reveals the presence of lymphoma in the vertebral body (*) 
of one of three bone BMT recipient rats, in which paralysis was not observed.  
 
While structural MRI was unable to detect the presence of any lesions in the T12-L3 region 
of the spinal column, H&E staining performed on sagittal cross section of the spinal cords 
revealed the presence of lymphomas within the vertebral body of one recipient (Figure 4.11). 
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4.4 Discussion: 
 
The presence of immunological abnormalities observed in A-T patients can contribute 
negatively towards the quality of life  in those suffering from this disease, with recurrent 
sino-pulmonary infections being common (Nowak-Wegrzyn, Crawford et al., 2004, Bott, 
Lebreton et al., 2007). As well as immunological dysfunction, leukemias are also common 
amongst patients with A-T, with B and T-cell leukemias, as well as lymphomas, developing 
in an estimated 10-15% of A-T patients by early adulthood (Taylor, Metcalfe et al., 1996). 
Currently the only bone marrow transplantations that have been performed on A-T patients 
have been used to treat the presence of leukemias or other immunological abnormalities in 
these individuals (Ghosh, Schuster et al., 2012, Ussowicz, Musial et al., 2013). However, if a 
preventive approach, in which BMT were to occur before the occurrence of any 
hematopoietic malignancies,  were beneficial enough to outweigh the risks associated with 
the transplantation procedure, such therapy may be worthy of consideration.  
 
Given the purported role of ATM in V(D)J recombination during T-cell development 
(Perkins, Nair et al., 2002, Matei, Guidos et al., 2006), analysis of T-cell populations in 
young (6-week) Atm -/-  rats was performed and there was found to be a decrease in the 
frequency of total (CD3+) T-cells in the thymus of these rats (Figure 4.1 E) Further, an 
increase in the frequency of CD3+/CD4+/CD8+ T-cell progenitor cells, relative to Atm +/+ 
rats. All of which is consistent with aberrant T-cell development associated with V(D)J 
recombination. This data is also consistent with studies performed in mouse models of A-T 
(Bagley, Cortes et al., 2004, Amabile, Welner et al., 2013). However, immunophenotyping of 
adult (4 month old) rat’s peripheral blood showed no significant difference between Atm -/- 
and Atm +/+, indicating that there may be a compensatory mechanism in place.  
 
The level of engraftment in these BMT experiments ranged from approximately 55-85% and 
generally decreased between 2 and 4 months post transplantation (Figure 4.4). This level of 
engraftment, as well as the decrease may be partially attributable to the fact that both the Atm 
-/- and Atm +/+ rats come from the same inbred background strain and therefore represent 
syngeneic rather than allogenic transplantation. As such, the donor cell mediated cell killing 
of residual bone marrow cells in the recipient after radiation that would be expected in an 
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allogenic transplant situation would not be present in this syngeneic environment (Li, Giver 
et al., 2009). Further, as ethics policies at our research facility would not facilitate the 
production of an LD50 curve in our Atm -/- rat models, and no such data exists in this novel 
model, it is possible that the radiation dose chosen was not adequate to facilitate complete 
ablation of the hematopoietic stem cell compartment. 
 
In spite of not achieving complete chimerism in these recipient animals, the bone marrow 
transplantation were effective in increasing the lifespan of these animals (Figure 4.6) with an 
increase in median lifespan from 6.3 to 10.1 months. However, the recipients still developed 
lymphomas (Figure 4.7) and showed irregular T-cell phenotypes in peripheral blood cell 
populations (Figure 4.8). The development of lymphomas in these BMT recipients may be a 
result of residual cells after irradiation and therefore an improved ablation regime may 
improve the success of transplantations. Further, given that this transplantation occurred 
between syngeneic donors and recipients further benefit might be obtained by the graft vs 
leukemia (GvL) effect of allogenic transplantation (Li, Giver et al., 2009), if the negative 
effects associated with allogenic transplantation, such as graft vs host disease, can be 
mediated.    
 
Of particular interest in these transplantation experiments, was the development of paralysis 
in only one of the fifteen rats that receive transplantation. MRI analysis of these rats did not 
reveal any lesions applying pressure on the spinal cord (Figure 4.10), such as those present in 
3/3 of the paralysed rats (Figure 3.11). However, pathology revealed the presence of some 
lymphoma within the vertebral body of one BMT recipient spine (Figure 4.11). As such, it 
appears that the BMT procedures may be affective in altering the frequency or rate of 
metastases of lymphomas to the spine.  
 
In conclusion these experiments indicate potential utility for BMT in the treatment 
hematopoietic phenotypes associated with A-T. The model would likely benefit by use of an 
outbred donor, giving the benefit of increased clinical relevance, as well as the potential 
benefits associated with a GvL response.  
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5.0 Conclusions and Future Directions 
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5.1 Expression of Histocompatibility 2, Blastocyst (H2-Bl) in embryonic stem cells 
inhibits CD8+ T-cell activation but is not sufficient to facilitate graft tolerance 
 
A-T is a disease with no current curative therapy and an unknown underlying etiology. Stem 
cell therapies may provide a potential treatment for these patients, however research in their 
utility for treatment in this disease is still in its infancy. One of the major barriers to utilizing 
pluripotent stem cells for treatment of diseases, such as this, is the potential for immune 
rejection of cells derived from pluripotent sources by the recipient’s immune system. With 
the advent of iPS cells, it has been proposed that this immunological barrier may not be as 
large of an issue, as a patient’s own cells could theoretically be used in these therapies. This 
becomes an issue, however, with diseases such as A-T, which are caused by mutations found 
in all of the patients cells. As such, reprogramming of these cells will still produce a 
pluripotent cell line harboring the causative mutation. Technologies are being developed for 
the correction of mutations in these cells. However, the correction, as well as the appropriate 
characterization of the corrected cells that will be required, is likely to remain costly and time 
consuming for some time. An alternative option, which we have considered here, is the 
generation of a universal donor embryonic stem cell line that will be tolerated by the immune 
system of all recipients.  
 
We chose the mouse homologue of the human HLA-G molecule (known as H2-Bl), as it has 
been shown to play a key role in maternal immune tolerance of the fetus (Rouas-Freiss, 
Goncalves et al., 1997).  Further, HLA-G has been shown to be capable of suppressing the 
CD8+ cytotoxic T lymphocytes response (Le Gal, Riteau et al., 1999). This is of direct 
importance to the potential immune tolerance of ESCs, CTL have been shown to be prevalent 
in the response to ESC transplantation (Magliocca, Held et al., 2006).  
 
After producing both hESCs and mESCs constitutively expressed the H2-Bl we tested to 
ensure that the introduction of this molecule did not interfere with proliferation, viability, or 
the differentiation capacity of these cells. However, one of the key benefits to using a 
universal donor cell line would be the ability to perform more in depth analysis on these 
potential donor cells, to help assure their safety and efficacy in a transplant situation. Full 
genome sequencing, as well as in vivo assays for teratomas formation and functional 
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integration would add greatly to this work, were modifications to become sufficient for graft 
tolerance. 
 
While the expression of H2-Bl in these cells lines was sufficient to decrease the CD8+ 
spleenocyte proliferation response in our assay, this alone was not enough to permit 
xenogenic or allogenic teratomas formation in immune competent mice. While teratomas 
formation has been successfully used as a surrogate for transplantation scenarios involving 
functional engraftment (Pearl, Lee et al., 2011, Guha, Morgan et al., 2013), it may not 
represent the best model for immune tolerance in ESC and iPSC transplantation biology, 
given that teratomas formation is an undesired outcome in such transplantations. Further the 
uncontrolled growth associated with teratoma formation places mechanic stresses on the 
tissues surrounding the injection site, which are unlikely to be representative of regular 
transplantation scenarios and may induce an innate immune response. However, given 
limitations in time and funding, as well as difficulties associated with obtaining animal ethics, 
it may be necessary to use this model for preliminary work on the immune tolerance of 
pluripotent cells and derived tissues.  
 
While cells expressing higher levels of the H2-Bl molecules were selected for, by performing 
titrations of puromycin, it is still possible that the level of expression was still not high 
enough. Given results indicating that the molecule is effective in inhibiting CD8+ T-cell 
proliferation, it may be worthwhile attempting to produce cells that express higher levels of 
this protein. This might be obtained by utilizing an alternate promoter with higher ubiquitous 
expression levels, or possible by performing a second transduction using the same virus.  
 
In conclusion, expression of the H2-Bl molecule in both mESC and hESC was not sufficient 
to facilitate teratomas formation in immune competent mice. However, it was shown to alter 
the CD8+ CTL response, indicating that it may be useful in facilitating graft tolerance in the 
future. Future experiments using H2-Bl, in conjunction with other immune suppression 
regimes, may be useful in producing a pluripotent cell capable of engraftment in multiple 
immune competent recipients. 
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5.2 Radiological Imaging of a Rat Model of Ataxia Telangiectasia 
    
While mouse Atm -/- models have proven to be useful tools in advancing the understanding 
mechanisms potentially responsible for many of the phenotypes associated with A-T  
(Barlow, Hirotsune et al., 1996, Elson, Wang et al., 1996, Xu and Baltimore, 1996, Kuljis, Xu 
et al., 1997, Herzog, Chong et al., 1998, Borghesani, Alt et al., 2000), the lack of prominent 
neurodegeneration limits the relevance of this model for treating this particular aspect of the 
disease. As such, our group generated an Atm -/- rat model which showed neural defects 
including microgliosis, dialated blood vessels in the eyes, and paralysis in ~50% of animals 
(Quek, Luff et al., 2015). The paralysis is of considerable interest as it demonstrates a serious 
neurological phenotype that could be indicative of neurodegenerations. 
 
However, MRI imaging of the brains of these animals did not detect any cerebellar atrophy, a 
hallmark of the disease in humans, which has been attributed to the neurological deficiencies 
observed in these patients. Given the restriction of the paralysis to the hind limbs in these 
rats, as well as the lack of detectable cerebellar atrophy, it is unlikely that this paralysis 
involves the cerebellum, Further, the presence of lymphomas within the spinal cord at the 
region associated with hind limb motility is consistent with the phenotype observed. 
 
Previous research from our group has proposed a role for microglial activation in the 
development of paralysis in these rats and  an elevated level of microglial activation in the 
brain of paralysed rats has been observed, as well as an influx of microglia in the lumbar 
region of the spinal cord at the time of paralysis. (Quek, Luff et al., 2015). It is possible that 
this elevated microglial activation in the spine also contributes towards the paralysis 
phenotype in these rats. However, it remains unclear as to whether this influx of microglia 
would be observed in the absence of lymphomas in this region. Given that  microglia are 
generally found within and surrounding tumours of the central nervous system CNS (da 
Fonseca and Badie, 2013) it seems plausible that their presence is secondary to the initiation 
of lymphomogenesis in this region. However, it is still possible that elevated microglial 
activation plays a role in the development of paralysis in these animals, independent of the 
presence of lymphomas.  
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Given that the development of lymphomas in the CNS may contribute to the presence of 
microglia as well as their activation, our PET studies focused on 5 month old animals which 
had not yet developed any paralysis and in which no lymphomas were detectable by MRI. 
Here we were unable to detect any significant differences in the number of activated 
microglia in the brain. Earlier work from our group found a difference in the frequency of 
activated microglia in the brains of rats at this age (Quek, Luff et al., 2015). However, as the 
PBR111 tracer only binds activated microglia, there is no measurement of non-activated 
microglia present. Therefore, the frequency of activation cannot be assessed. Further, it is 
possible that the level of total activated microglia is still slightly higher in the brain of Atm -/- 
rats, relative to Atm +/+ rats, but falls below the limit of detection obtainable with this 
imaging modality.   
 
In conclusion, it seems that the presence of paralysis (the primary neurological defect 
observed in this rat model) is the result of the presence of lymphomas within the L12-T3 
region of the spine. This model may still prove to be useful in the elucidation of mechanisms 
associated with A-T and may prove valuable for assessing the therapeutic potential of 
multiple treatment modalities in A-T.  
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5.3 Bone Marrow Transplantation in a Rat Model of Ataxia Telangiectasia 
 
Of all of the potential stem cell based therapies for treatment in A-T, BMT seems the most 
likely to be clinically available on a short term basis. As such, BMTs were performed in our 
rat model to assess whether this might be beneficial and worthwhile. These transplantations 
resulted in a significant delay in the presence of lymphomas within these animals, indicating 
such procedures may be we worthwhile for ameliorating hematopoietic phenotypes 
associated with this disease.   
 
Further experiments utilizing this model could benefit from some minor changes, which may 
further improve the success of transplantations and increase their clinical relevance. Given 
that A-T is associated with radiation sensitivity, future transplant scenarios would likely 
benefit from the use of alternative methods for the ablation of hematopoietic cells within 
recipients, that do not involve the production of ROS and DNA double strand breaks.  
 
The level of engraftment in these experiments was also fairly low and seemed to decrease 
over time. This indicates that the recipient’s hematopoietic stem cell compartment was not 
completely ameliorated from the irradiation. These engraftment levels may be improved 
using a donor rat from a different genetic background allowing for donor cell mediated 
killing of residual bone marrow cells within the recipient. This would also make the model 
more clinically relevant, and better assess the role that graft vs host disease (GVHD) might 
play in the success of bone marrow transplantation in A-T patients.  
 
In conclusion, bone marrow transplantation in patients with A-T may have potential for the 
treatment of hematological malignancies associated with this disease. Further experiments 
could better improve the assessment of this risk, and help define new strategies for the 
treatment of this disease. 
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